The Weekly Term Sheet (2026-W15)
April 5–10, 2026 saw $9.2 billion in confirmed capital deployed across biopharma, spanning 6 M&A transactions, 6 licensing deals, 3 structured debt/royalty facilities, 14 equity raises, 2 government contracts, and 1 fund close — plus 7 clinical readouts and 5 regulatory actions. Oncology dominated at $3.7 billion (40% of total), followed by rare disease ($3.1 billion) and neuroscience ($490 million).
W15 by the numbers
| Category | Confirmed capital | Deal count |
|---|---|---|
| M&A (upfront cash) | $6.7 billion | 6 |
| Structured debt & synthetic royalties | $510 million | 3 |
| Equity raises (public, private, ATM) | $1.75 billion | 14 |
| Government contracts (initial awards) | $145 million | 2 |
| Licensing upfronts | $113 million | 6 |
| Total confirmed | $9.2 billion | 31 |
Headline deal values including contingent milestones push the theoretical total above $17 billion — but the $9.2 billion figure above reflects only binding upfront commitments, closing payments, and committed facilities.
Most active acquirers and partners
Gilead Sciences accounted for four separate transactions in the W15 window alone (Tubulis $3.15B acquisition, Kymera KT-200 $45M option exercise, Cartography first target option, and a pre-existing Tempus AI data collaboration), bringing its total 2026 M&A and licensing commitments to approximately $15 billion.
Eli Lilly appeared three times as a licensing counterparty (AC Immune $12.5M amendment, Nxera development milestone, Foundayo commercial launch triggering Chugai royalties). Boehringer Ingelheim was the week's most prolific collaborator with three distinct transactions across three modalities: the BioNTech SCLC clinical trial collaboration, the Click Therapeutics $50M Series D and rights transfer, and the Cue Biopharma $7.5M preclinical milestone.
Most active advisors
Guggenheim Securities led with four mandates: sell-side financial advisor to Soleno, bookrunner on the Forte Biosciences and Celldex public offerings, and bookrunner on the Avalyn Pharma IPO. Leerink Partners appeared on three transactions (Adagene and Celldex bookrunner, Terns/Merck sell-side). On the legal side, Wilson Sonsini advised on three deals (Soleno sell-side, Sidewinder Series B, Avalyn Series D), while Goodwin Procter handled three as well (Tubulis sell-side, SWK/Runway merger, Denali/Royalty Pharma synthetic royalty). Centerview Partners appeared on both sides of the week's two largest M&A deals — sell-side for Soleno and buy-side for Gilead/Tubulis.
Most active investors (private rounds)
Qiming Venture Partners co-led two rounds (Oricell $110M pre-IPO, Vivatides $54M Series A). GV (Google Ventures) participated in two (Stipple Bio Series A, Beacon Biosignals Series B extension).
The ADC subsector attracted the heaviest private capital concentration, with Stipple Bio ($100M Series A, co-led by RA Capital, a16z Bio+Health, Nextech Invest) and Sidewinder Therapeutics ($137M Series B, co-led by Frazier Life Sciences and Novartis Venture Fund) together raising $237 million for preclinical ADC programs in a single week. Jeito Capital closed Jeito II at $1.2 billion — the largest fully independent European biopharma fund ever raised.
Therapeutic area breakdown (confirmed capital)
| Therapeutic area | Confirmed capital | Key transactions |
|---|---|---|
| Oncology (all modalities) | $3.7 billion | Gilead/Tubulis, Kymera, C4T/Roche, Stipple Bio, Sidewinder, Oricell, IDEAYA/AZ |
| Rare disease | $3.1 billion | Neurocrine/Soleno, Ascendis YUVIWEL launch, Denali/RPRX payment |
| Neuroscience | $490 million | Korsana/Cyclerion PIPE, Praxis elsunersen, AC Immune/Lilly, Beacon Biosignals |
| Autoimmune / Dermatology | $495 million | Celldex $345M offering, Forte $150M offering |
| Ophthalmology / Gene therapy | $240 million | Oberland/Opus Genetics, Dyno/Astellas, Life Biosciences |
| Metabolic / Obesity | N/A (commercial launches) | Foundayo $149/month, Wegovy HD $399/month — pricing war week |
| Sleep / Respiratory | $150 million | HCRx/Apnimed |
| Anti-infectives | $119 million | Shionogi/BARDA Fetroja |
Week in context
The W15 window was bracketed by two GLP-1 commercial launches that will reshape the obesity market's royalty economics: Lilly's Foundayo (triggering Chugai's mid-single-digit to low-teens tiered royalty on what consensus expects to be a $1.5–2.8B first-year product) and Novo's Wegovy HD (royalty-clean, priced at $399/month to undercut Zepbound).
On the deal side, the ADC modality continued its dominance: Gilead's $3.15B Tubulis acquisition, the C4T/Roche degrader-antibody conjugate platform deal, IDEAYA/AZ's DLL3 ADC clinical collaboration, and $237M in private ADC company financing (Stipple Bio + Sidewinder) collectively confirm ADCs as the single largest capital attractor in oncology dealmaking.
At the SGO 2026 Annual Meeting, Corcept's ROSELLA final OS data (35% death risk reduction, published in The Lancet) established Lifyorli as a new standard of care in platinum-resistant ovarian cancer — royalty-clean on the current indication. Zentalis selected its pivotal azenosertib dose for the same indication, setting up a potential two-drug competitive dynamic by 2027–2028.
Eli Lilly / Chugai Pharmaceutical: Foundayo Commercial Launch and the Royalty Stack Behind the Pill (April 6)
Eli Lilly (NYSE: LLY) began shipping Foundayo (orforglipron) to patients via LillyDirect on April 6, 2026, five days after the April 1 FDA approval.
Foundayo is the first oral small-molecule GLP-1 receptor agonist approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. It was also the fastest drug review since 2002.
Pricing: $649/month WAC, with a self-pay cash price of $149/month and commercial insurance copays as low as $25/month via savings card. Medicare Part D pricing of $50/month begins July 1. Lilly had pre-built $1.5 billion in launch inventory as of December 31, 2025.
The Chugai Royalty
Foundayo was not discovered by Lilly. Orforglipron (then designated OWL833, or Compound 67) was invented by scientists at Chugai Pharmaceutical (TYO: 4519), a Roche-majority-owned Japanese company, and licensed to Lilly on September 26, 2018. The 2018 agreement has never been publicly amended.
Chugai Pharmaceutical is majority-owned by Roche (59.89% stake). Roche held a right of first refusal on the compound under its Chugai strategic alliance and assessed OWL833 in 2018 — declining to exercise it, reportedly viewing obesity as a non-priority following its 2010 taspoglutide failure. Roche does not hold a direct interest in the Chugai-Lilly royalty stream.
It later re-entered obesity via its $3.1 billion acquisition of Carmot Therapeutics in 2024.
Deal Structure (2018 License)
| Term | Detail |
|---|---|
| Licensor | Chugai Pharmaceutical Co., Ltd. (TYO: 4519) |
| Licensee | Eli Lilly and Company (NYSE: LLY) |
| Effective date | September 26, 2018 |
| Upfront payment | $50 million |
| Regulatory milestones | Up to $140 million |
| Commercial/sales milestones | Up to $250 million |
| Royalties | Tiered, mid-single digits to low teens on worldwide net sales |
| Rights granted | Worldwide development, manufacturing, and commercialization |
The royalty rate is disclosed only as a band — "mid-single digits to low teens" — in Lilly's 10-K. Chugai's Q4 2025 earnings call confirmed that the increase in non-Roche royalty income in FY2026 guidance is "overwhelmingly" attributable to orforglipron, while declining to disclose the specific tier structure.
Chugai has guided FY2026 royalty and profit-sharing income of ¥217.2 billion (+25.8% YoY).
Sales Projections and Royalty Scenarios
Wall Street consensus places 2026 Foundayo net sales in the $1.5–$2.8 billion range, with peak estimates ranging from $10 billion (conservative) to $14–15 billion (median analyst cluster) to $40 billion+ (Citi bull case).
Lilly's full-year 2026 guidance of $80–83 billion revenue implicitly embeds a significant Foundayo contribution.
Applying the disclosed royalty band to plausible sales scenarios:
| Scenario | Blended effective rate | 2026 royalty (at $2B net sales) | Peak royalty (at $15B) |
|---|---|---|---|
| Conservative | ~4–6% | $80–120M | $600–900M |
| Mid-case | ~7–8% | $140–160M | $1.05–1.2B |
| Bull case | ~9–10% | $180–200M | $1.35–1.5B |
These are illustrative estimates based on the disclosed range. No independent confirmation of the precise tier breakpoints has been identified. The April 1 FDA approval likely triggered a portion of the $140 million regulatory milestone tranche; combined with the $50 million upfront (paid 2018) and up to $250 million in sales milestones, total non-royalty deal value reaches $440 million.
Novo Nordisk released its ORION indirect treatment comparison on April 2, claiming oral semaglutide 25mg achieved 3.2 percentage points greater mean weight loss than orforglipron 36mg with lower GI-related discontinuation rates. However, ORION was a population-adjusted indirect comparison (not a head-to-head trial) with extremely wide confidence intervals, and analysts generally view oral GLP-1 competition as market-expanding rather than zero-sum.
Foundayo retains differentiated advantages: no food or water restrictions, small-molecule manufacturing scalability, and aggressive Lilly pricing.
Patent Duration and Royalty Term
Chugai's foundational compound patent (WO2018056453, priority ~September 2017) carries a standard 20-year expiry of approximately 2037. Lilly may obtain up to five years of patent term extension as a new molecular entity, potentially extending protection to 2041–2042. An active USPTO PGR challenge (PGR2025-00057) targets at least one Lilly patent but does not appear to threaten the Chugai compound patents.
The royalty term under the 2018 agreement was not disclosed; standard practice in deals of this vintage ties the royalty obligation to the later of patent expiry or regulatory exclusivity expiration.
No royalty monetization of the Chugai-Lilly orforglipron stream has been identified. Chugai retains the full royalty interest.
Upstream IP and Royalty Stack
| Layer | Direction | Recipient | Est. Rate |
|---|---|---|---|
| Chugai Pharmaceutical | Outflow from Lilly | Chugai | ~4–13% tiered (est.) |
| Academic or platform licenses | None identified | — | 0% |
| Roche (via Chugai equity) | Indirect / equity | Roche (59.89% shareholder) | N/A — equity, not royalty |
| Total identified royalty outflow from Lilly | ~4–13% |
Neurocrine Biosciences / Soleno Therapeutics: $2.9 Billion Rare Disease Acquisition (April 6)
On April 6, Neurocrine Biosciences (NASDAQ: NBIX) and Soleno Therapeutics (NASDAQ: SLNO) announced a definitive agreement under which Neurocrine will acquire all outstanding shares of Soleno for $53.00 per share in cash, representing an aggregate equity value of approximately $2.9 billion.
This is Neurocrine's first major acquisition.
Soleno shares rose approximately 33% on the announcement.
Deal Structure
| Term | Detail |
|---|---|
| Acquirer | Neurocrine Biosciences, Inc. (NASDAQ: NBIX) |
| Target | Soleno Therapeutics, Inc. (NASDAQ: SLNO) |
| Cash consideration | $53.00 per share |
| Aggregate equity value | ~$2.9 billion |
| Premium (April 2 close) | 34% |
| Premium (30-day VWAP) | 51% |
| Financing | Cash on hand plus pre-payable debt; no financing condition |
| Termination fee (Soleno) | $95.25 million |
| Reverse termination fee (Neurocrine) | $141.5 million |
| Outside date | October 5, 2026 |
| Structure | All-cash tender offer followed by back-end merger |
| Neurocrine financial advisor | Goldman Sachs & Co. LLC (exclusive) |
| Neurocrine legal counsel | Cooley LLP |
| Soleno financial advisors | Centerview Partners LLC and Guggenheim Securities |
| Soleno legal counsel | Wilson Sonsini Goodrich & Rosati |
Asset Acquired: VYKAT XR (Diazoxide Choline)
VYKAT XR (diazoxide choline controlled-release) is the first-in-class and only FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder affecting hypothalamic function. The FDA granted approval in March 2025. VYKAT XR generated $190 million in FY2025 net sales ($92 million in Q4 alone), with HC Wainwright estimating peak sales of $2.3 billion.
Approximately 440,000 patients are estimated to have PWS globally, with significant under-diagnosis.
The acquisition extends Neurocrine's commercial infrastructure beyond its core neuroscience franchise (ingrezza, Corcept collaboration) into metabolic rare disease — a new therapeutic area for the company.
Upstream IP and Royalty Stack
Diazoxide is a well-characterized generic compound with expired underlying chemistry patents. VYKAT XR's proprietary value rests in its controlled-release formulation (Soleno-invented IP) and the clinical evidence base supporting the hyperphagia indication in PWS. The NDA was filed under the 505(b)(2) pathway, referencing prior literature for the parent molecule without requiring a third-party license.
Soleno developed both the novel choline salt form and the extended-release formulation internally. No upstream royalties to academic institutions or prior compound licensors were identified in Soleno's 10-K or public filings. Neurocrine inherits a royalty-unencumbered commercial asset, subject only to standard manufacturing and supply arrangements.
Six U.S. patents are listed in the Orange Book for VYKAT XR, with expiration dates ranging from 2025 to 2035. The commercially critical method-of-use patents for PWS extend through 2034–2035. Orphan Drug Exclusivity provides additional protection through approximately March 2032. No Paragraph IV challenges or ANDA filings have been identified. The SC 14D-9 filing, when available, will be the definitive source for any undisclosed encumbrances.
| Layer | Direction | Recipient | Est. Rate |
|---|---|---|---|
| Academic / prior compound license | None identified — all diazoxide choline patents (inventors: Neil Cowen, Kenneth Kashkin, Khaled Yamout) assigned to Essentialis, Inc., not a university | — | 0% |
| Essentialis contingent milestones | Outflow from Soleno/Neurocrine | Former Essentialis stockholders | ~$14.2M remaining — the first $100M cumulative revenue milestone (~$7M payment) was triggered Q4 2025; the second ($200M cumulative) appears imminent given $190.4M in FY2025 nine-month revenue |
| Total royalty burden on VYKAT XR net sales | ~0% ongoing royalty; one-time milestone payments only |
Gilead Sciences / Tubulis GmbH: $3.15 Billion ADC Acquisition (Up to $5B with Milestones) (April 7)
On April 7, Gilead Sciences (NASDAQ: GILD) announced a definitive agreement to acquire Tubulis GmbH, a privately held Munich-based antibody-drug conjugate company, for $3.15 billion upfront in cash (on a cash-free, debt-free basis) plus up to $1.85 billion in contingent development and commercial milestone payments — a headline value of up to $5 billion, though the binding commitment at close is $3.15 billion. This is Gilead's third acquisition of 2026, following Arcellx ($7.8 billion, cell therapy) and Ouro Medicines (~$2.1 billion), bringing Gilead's total 2026 M&A spend to approximately $15 billion.
Deal Structure
| Term | Detail |
|---|---|
| Acquirer | Gilead Sciences, Inc. (NASDAQ: GILD) |
| Target | Tubulis GmbH (private, Munich) |
| Upfront cash (at close) | $3.15 billion (cash-free, debt-free) |
| Contingent milestones | Up to $1.85 billion |
| Headline deal value | Up to $5.0 billion |
| Additional contingent consideration | Up to ~$58 million |
| Financing | Cash on hand + senior unsecured notes |
| Expected close | Q2 2026 |
| Pre-existing relationship | Two-year research collaboration (December 2024) |
| Gilead financial advisors | Centerview Partners and Allen & Company |
| Gilead legal counsel | Covington & Burling, Arnold & Porter, and Venable LLP |
| Tubulis financial advisor | J.P. Morgan Securities |
| Tubulis legal counsel | Goodwin Procter and CMS Hasche Sigle |
Assets Acquired
The deal brings Gilead two clinical-stage ADCs and a proprietary linker-payload technology platform:
TUB-040 is a NaPi2b-directed topoisomerase-I inhibitor ADC in Phase 1b/2 for platinum-resistant ovarian cancer and NSCLC, having demonstrated a 59% overall response rate in ovarian cancer at ESMO 2025. TUB-030 is a 5T4-targeted ADC with early clinical data across multiple solid tumor types. Both candidates utilize Tubulis's proprietary Tubutecan linker-payload platform, which enables improved conjugation stability relative to conventional ADC chemistry.
Tubulis will operate as a dedicated ADC research organization within Gilead, with Munich serving as a global ADC innovation hub.
Upstream IP and Royalty Stack
Tubulis was co-founded in 2019 as a joint spin-out of Ludwig-Maximilians-Universität (LMU) Munich and the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) Berlin. The two core technologies have distinct academic origins: P5 conjugation (cysteine-selective chemistry) was invented at FMP Berlin by Marc-André Kasper during his doctoral thesis under Prof. Christian Hackenberger; the Tub-tag® technology (enzyme-based site-specific conjugation) was developed at LMU Munich by Prof. Heinrich Leonhardt and Dr. Jonas Helma-Smets. Dr.
Dominik Schumacher (co-founder, CSO) bridged both institutions. Existing Tubulis investors include EQT Life Sciences, Andera Partners (BioDiscovery 6), Bayern Kapital, and the European Innovation Council Fund, all of whom are exiting through the Gilead acquisition. Evotec SE (NASDAQ: EVO), which holds a 3.14% equity stake in Tubulis, is expected to receive approximately $100 million in upfront consideration at close.
The company had previously raised approximately €175 million across Series A, B, and B2 rounds. Prof. Leonhardt has publicly confirmed that "a portion of these proceeds will flow back to LMU and FMP through licensing agreements" — confirming active royalty-bearing license agreements, though specific rates remain confidential.
Gilead also inherits Tubulis's pre-existing third-party licensing obligations, most notably a Bristol-Myers Squibb strategic license ($22.75 million upfront, over $1 billion in milestones, tiered royalties on net sales) and the December 2024 Gilead option agreement itself (mid-single to low-double-digit tiered royalties, $35 million upfront + up to $380 million in milestones).
Whether the exatecan-class payload chemistry in the Tubutecan platform carries any upstream obligations (e.g., to Daiichi Sankyo for the compound class) was not publicly confirmable.
Licensing: Gilead Sciences / Kymera Therapeutics — KT-200 CDK2 Molecular Glue Degrader Option Exercise ($45M Milestone) (April 9)
On April 9, Kymera Therapeutics (NASDAQ: KYMR) announced that Gilead Sciences (NASDAQ: GILD) has exercised its exclusive option to license KT-200, a first-in-class oral CDK2 molecular glue degrader development candidate discovered and characterized by Kymera.
The option exercise triggers a $45 million milestone payment, bringing cumulative payments to $85 million ($40M upfront from June 2025 + $45M option exercise). Kymera remains eligible for up to $750 million in total payments including milestones and tiered royalties on net sales. Gilead will advance KT-200 into IND-enabling studies targeting an IND filing in 2027.
KT-200 targets CCNE1-amplified solid tumors with preclinical data demonstrating potent CDK2 degradation, anti-tumor activity, and brain-penetrant potential. This is Gilead's fourth pipeline-expanding deal announced during the W15 window (alongside Tubulis, Cartography, and Tempus AI), underscoring an oncology transformation strategy that has seen approximately $15 billion in total 2026 M&A and licensing commitments.
| Term | Detail |
|---|---|
| Licensor | Kymera Therapeutics, Inc. (NASDAQ: KYMR) |
| Licensee | Gilead Sciences, Inc. (NASDAQ: GILD) |
| Asset | KT-200 (oral CDK2 molecular glue degrader) |
| Original collaboration | June 2025 |
| Upfront (original) | $40 million |
| Option exercise milestone | $45 million (April 2026) |
| Total potential payments | Up to $750 million |
| Royalties | High single-digit to mid-teens % tiered on net sales |
| IND timeline | 2027 |
Licensing: Gilead Sciences / Cartography Biosciences — First Oncology Target Option Exercise (April 9)
On April 9, Cartography Biosciences (private, South San Francisco) announced that Gilead Sciences has exercised the first of its options to exclusively license a novel oncology target discovered and validated through Cartography's proprietary ATLAS and SUMMIT single-cell platforms. The option exercise advances a target in triple-negative breast cancer (TNBC) and NSCLC adenocarcinoma.
Gilead assumes full downstream development and commercialization responsibility. Financial terms of the option exercise were not separately disclosed; the original May 2024 collaboration included a $20 million upfront with additional option fees, milestones, and royalties. Cartography's platforms translate proprietary single-cell datasets into cell-specific antibody-based cancer therapies.
HealthCare Royalty Partners / Apnimed: $150 Million Debt-Plus-Royalty Financing (April 6)
On April 6, Apnimed (private, Cambridge, MA) announced it had secured a senior secured credit facility of up to $150 million from HealthCare Royalty Partners (HCRx), the royalty acquisition firm founded in 2006 that is now majority-owned by KKR (NYSE: KKR) following its July 2025 acquisition. HCRx has committed over $7 billion across 110+ biopharmaceutical products since inception.
The financing is structured in three tranches and includes a synthetic royalty component on future AD109 net sales. The capital is earmarked for commercial readiness activities and the planned U.S. launch of AD109, if approved.
Deal Structure
| Term | Detail |
|---|---|
| Lender | HealthCare Royalty Partners (KKR-majority-owned) |
| Borrower | Apnimed, Inc. (private) |
| Facility | Senior secured credit facility |
| Total commitment | Up to $150 million |
| Tranche 1 | $50 million at closing |
| Tranche 2 | $50 million upon FDA approval of AD109 |
| Tranche 3 | $50 million upon achievement of a commercial sales milestone |
| Interest structure | Interest-only for 4 years, extendable to 5 years upon achievement of a specified net sales milestone |
| Royalty component | Low single-digit percentage of net sales of AD109 and certain other specified Apnimed revenues |
| Asset | AD109 (aroxybutynin + atomoxetine combination) for obstructive sleep apnea |
| NDA timeline | Submission expected Q2 2026 |
Asset Context: AD109 in Obstructive Sleep Apnea
AD109 is a first-in-class oral pharmacotherapy for obstructive sleep apnea (OSA), combining a muscarinic receptor antagonist (aroxybutynin) with a norepinephrine reuptake inhibitor (atomoxetine) in a proprietary co-formulation designed to target the underlying neuromuscular cause of upper airway collapse during sleep. Two positive Phase 3 trials (SynAIRgy, LunAIRo) have been completed. OSA affects an estimated 80 million people in the United States and one billion people worldwide; CPAP non-adherence remains high, creating a substantial unmet need for pharmacological alternatives.
If approved, AD109 would be the first oral drug approved for OSA.
Upstream IP and Royalty Stack
Apnimed was founded in 2017 directly from research at Brigham and Women's Hospital (BWH) by Andrew Wellman, MD, PhD and Luigi Taranto-Montemurro, MD, who conducted the proof-of-concept experiment combining atomoxetine and oxybutynin in OSA patients. The foundational patent (WO2018200775A1, "Methods and compositions for treating sleep apnea," assigned to BWH) has yielded U.S. Patents 11,123,313 and 11,911,351. CEO Larry Miller negotiated the rights to the patents from Harvard upon founding.
Harvard's Office of Technology Development almost certainly retains a royalty interest, consistent with standard academic tech transfer practices, though specific rates are undisclosed given Apnimed's private status. Estimated at low single-digit % based on comparable BWH/Harvard spinout licenses.
Aroxybutynin and atomoxetine are both well-characterized compounds with expired composition-of-matter patents; Apnimed's IP rests in the co-formulation and clinical evidence base. The $100 million Shionogi buyout of Apnimed's 50% JV stake (W13) involved only the Shionogi-Apnimed Sleep Science (SASS) joint venture; AD109 and AD504 were explicitly excluded from SASS at its 2023 formation, and Shionogi retains no royalty interest in AD109.
| Layer | Direction | Recipient | Est. Rate |
|---|---|---|---|
| Harvard/BWH academic license | Outflow from Apnimed | Harvard OTD | Low single-digit % (est.) |
| HCRx synthetic royalty (new) | Outflow from Apnimed | HCRx / KKR | Low single-digit % |
| Compound IP (aroxybutynin/atomoxetine) | None identified | — | 0% |
| Total royalty burden on AD109 net sales | ~2–5% (est.) |
Oberland Capital / Opus Genetics: $160 Million Structured Note Facility for Gene Therapy (April 6)
On April 6, Opus Genetics (NASDAQ: IRD) announced a strategic long-term financing of up to $155 million in senior secured notes from Oberland Capital Management, plus a concurrent $5 million equity investment at $4.48 per share.
Deal Structure
| Term | Detail |
|---|---|
| Lender | Oberland Capital Management |
| Borrower | Opus Genetics, Inc. (NASDAQ: IRD) |
| Facility | Senior secured notes |
| Total commitment | Up to $155 million (notes) + $5 million (equity) |
| Tranche 1 | $35 million at initial closing (~April 20, 2026) |
| Tranche 2 | $35 million at Opus's option within 12 months |
| Tranche 3 | $25 million upon FDA Application Acceptance for LCA5 (by March 2028) |
| Tranche 4 | Up to $50 million by mutual agreement (through December 2027; uncommitted) |
| Total committed | $105 million ($50M uncommitted at lender discretion) |
| Maturity | April 2, 2033 (7 years from initial issuance) |
| Interest rate | Floating, Term SOFR with 3.68% floor + margin; ~4.1% initial cash rate |
| PIK feature | 50% of interest paid-in-kind for first 8 quarters per tranche |
| Interest-only period | 6 years; 50% principal repayment on 6th anniversary |
| Conversion feature | Up to 10% of principal convertible to common stock at $6.72/share |
| Equity co-investment | $5 million at $4.48/share |
| Pro forma cash | ~$100 million; runway extended through 2029 |
The capital funds pivotal studies for OPGx-LCA5 and OPGx-BEST1, gene therapies for inherited retinal diseases, plus earlier-stage programs (OPGx-RDH12 entering U.S. trials Q4 2026, OPGx-MERTK end of 2026, OPGx-RHO in 2027) and the commercial ophthalmology product Phentolamine Ophthalmic Solution 0.75%.
Opus was launched in 2021 as the first internally conceived spinout of the RD Fund, the investment arm of the Foundation Fighting Blindness. The company's scientific foundation draws on research from Jean C. Bennett (University of Pennsylvania) and Eric Pierce (Harvard University / Massachusetts Eye and Ear). Three-month topline results from the full Cohort 1 of the Phase 1/2 OPGx-BEST1 trial remain on track for mid-2026.
The structure is notable for royalty watchers: while the disclosed terms describe a senior secured note facility rather than a synthetic royalty, Oberland Capital — a specialist in royalty and milestone-linked biopharmaceutical financings — typically incorporates revenue-linked components in its structured deals. The tranche-gating mechanism (Tranche 3 contingent on a regulatory milestone) mirrors the milestone-linked drawdown structures seen in recent HCRx and DRI transactions.
SWK Holdings / Runway Growth Finance Corp: Merger Closes (April 6)
On April 6, SWK Holdings Corporation (NASDAQ: SWKH) completed its merger into Runway Growth Finance Corp (NASDAQ: RWAY), a business development company backed by BC Partners Credit. SWK stockholders approved the transaction on March 31 (93% quorum).
SWK Holdings ceases to exist as an independent publicly traded company.
SWK was one of the only U.S.-listed vehicles dedicated exclusively to sub-$50 million life sciences royalty and revenue-interest financings, having deployed approximately $876 million across 58 parties since inception. SWK sold the majority of its royalty portfolio in early April 2025 for $34 million; the historical book had included royalties on Narcan Nasal Spray, Beleodaq, Besivance, Cambia, and Forfivo XL, plus assets acquired from PDL BioPharma. ANI Pharmaceuticals bought out the Iluvien royalty for $17.3 million in March 2025.
By the time of merger close, the remaining royalty positions were modest, and the strategic value of the combination lies primarily in SWK's $136 million+ structured term loan portfolio and its wholly-owned CDMO subsidiary MOD3 Pharma (formerly Enteris BioPharma). The combined entity's healthcare portfolio exposure rises from approximately 14% to approximately 31% of Runway's ~$1.3 billion total assets.
Deal Structure
| Term | Detail |
|---|---|
| Acquiring entity | Runway Growth Finance Corp (NASDAQ: RWAY) |
| Absorbed entity | SWK Holdings Corporation (NASDAQ: SWKH) |
| Majority owner (RWAY) | BC Partners Credit |
| Total purchase price | $249 million ($75.5M RWAY shares + $173.5M cash + $9M from adviser) |
| Per-share consideration | 1.7264 RWAY shares (stock election) or $20.59 cash (cash election) + $0.74/share adviser payment |
| Approval date | March 31, 2026 (SWK shareholder vote, 99.9% approval) |
| Close date | April 6, 2026 |
| RWAY assumed debt | $30M of SWK's 9.00% Senior Notes due 2027 |
| Pro forma total assets | ~$1.2 billion |
| SWK historical deployment | ~$876 million across 58 life sciences parties |
| Healthcare % of combined portfolio | ~32% (up from ~14%) |
| SWK financial advisor | KBW / Stifel |
| SWK legal counsel | Goodwin Procter LLP |
| Runway legal counsel | Simpson Thacher & Bartlett LLP |
Acquisition: Garda Therapeutics / Assertio Holdings — $125.1 Million Take-Private with Concurrent Cosette Asset Sale (April 8)
On April 8, Assertio Holdings (NASDAQ: ASRT) announced a multi-pronged transaction: Garda Therapeutics will acquire the company via cash tender offer at $18.00 per share (~$125.1 million total) plus a non-tradeable contingent value right (CVR) tied to future Sprix milestones.
The deal represents a 34.6% premium to Assertio's unaffected stock price and 62.2% to the 60-day VWAP. Garda's primary interest is Assertio's oncology supportive care asset Rolvedon (eflapegrastim-xnst).
A 20-day window-shop provision allows Assertio to solicit competing bids at a reduced breakup fee. Closing is expected Q2 2026.
Simultaneously, Assertio signed and closed a separate asset sale to Cosette Pharmaceuticals for $35 million upfront plus milestones, divesting seven branded products: Sympazan (epilepsy, patent to 2040), Indocin, Sprix, Zipsor, Cambia, and Otrexup. These products generated approximately $48.9 million in 2025 net sales.
The concurrent structure allows Garda to focus exclusively on the Rolvedon franchise while Cosette expands its branded specialty portfolio.
Deal Structure
| Term | Detail |
|---|---|
| Acquirer | Garda Therapeutics (private) |
| Target | Assertio Holdings, Inc. (NASDAQ: ASRT) |
| Cash consideration | $18.00 per share (~$125.1 million) |
| Premium (unaffected) | 34.6% |
| Premium (60-day VWAP) | 62.2% |
| CVR | Non-tradeable; tied to Sprix milestones |
| Structure | Cash tender offer followed by back-end merger |
| Go-shop provision | 20 days; reduced breakup fee during window |
| Expected close | Q2 2026 |
| Concurrent asset sale | Seven branded products to Cosette Pharmaceuticals |
| Cosette upfront | $35 million |
| Cosette products | Sympazan, Indocin, Sprix, Zipsor, Cambia, Otrexup, plus one additional |
| 2025 net sales (divested products) | ~$48.9 million |
Upstream IP and Royalty Stack: Rolvedon
Rolvedon (eflapegrastim-xnst) was developed by Hanmi Pharmaceutical Co., Ltd. (KRX: 128940) using its proprietary LAPSCOVERY technology and licensed to Spectrum Pharmaceuticals in October 2014 (option exercised under a January 2012 agreement). Assertio acquired Spectrum in July 2023 for the Rolvedon asset.
The Hanmi royalty terms were restructured in January 2022: the original tiered royalties of low double digits to mid-teens on annual net sales were replaced by a flat mid-single-digit royalty on aggregate annual net sales, plus a supplemental mid-single-digit royalty beginning in Year 3 post-launch — the supplemental royalty terminates once cumulative supplemental payments reach $10 million. Hanmi also retains rights in Korea, China, and Japan. Hanmi manufactures the drug substance at its Korean facility.
The amended supply agreement (October 2025) includes a mid-single-digit percentage price reduction.
Garda inherits the full Hanmi royalty and supply obligations upon closing.
The seven products divested to Cosette are largely mature branded small molecules with no disclosed third-party royalty obligations at time of sale — Sympazan's patent-to-2040 provides the most durable revenue stream in the Cosette portfolio.
| Layer | Direction | Recipient | Est. Rate |
|---|---|---|---|
| Hanmi Pharmaceutical (Rolvedon license) | Outflow from Assertio/Garda | Hanmi (KRX: 128940) | Mid-single digit % flat royalty + supplemental mid-single digit % (capped at $10M cumulative) |
| Academic/upstream on Rolvedon | None identified | — | 0% |
| Cosette products (divested) | No royalties identified | — | 0% |
| Total royalty burden on Rolvedon net sales | ~5–10% (transitional; declining to ~5% after supplemental cap met) |
Regulatory: Orca-T PDUFA Passes as Non-Event (April 6)
The April 6 PDUFA date for Orca Bio's Orca-T BLA in hematologic malignancies was superseded by the April 1 announcement that FDA had extended the review by three months. The new PDUFA target action date is July 6, 2026. The extension follows Orca Bio's submission of updated CMC information in response to FDA requests, classified as a Major Amendment.
No additional clinical data were requested.
The Precision-T Phase 3 data remain intact: 1-year overall survival of 94% vs. 83% for conventional allogeneic HSCT (HR 0.49), non-relapse mortality of 3% vs. 13%, and grade 3/4 acute GVHD of 6% vs. 17%. Orca Bio holds Priority Review, RMAT, and Orphan Drug designations and raised $250 million in Series F in December 2025 for commercial readiness.
Orca Bio is privately held. Its technology originated at Stanford University under an exclusive license from the Irv Weissman laboratory at the Stanford Institute for Stem Cell Biology and Regenerative Medicine. Both the therapeutic platform (high-purity cell sorting) and manufacturing technology are Stanford-licensed, with foundational patents jointly assigned to Stanford and Orca Biosystems (e.g., WO2018053485A1).
Specific royalty rates are undisclosed given Orca Bio's private status, but based on Stanford OTL's standard practices for comparable spinouts, the license likely includes an equity stake and earned royalties estimated at low-to-mid single digits on product sales — a reach-through obligation that would apply across Orca Bio's full product portfolio (Orca-T, Orca-Q, and future programs).
Equity Raises: Stipple Bio Emerges from Stealth with $100 Million Series A (April 6)
Stipple Bio (private, Cambridge, MA) debuted from stealth on April 6 with a heavily oversubscribed $100 million Series A to advance its lead ADC candidate STP-100 into early clinical studies and build out a precision oncology pipeline leveraging its proprietary Pointillist platform.
The round is expected to fund the company through 2029.
The Series A was co-led by RA Capital Management, a16z Bio+Health, and Nextech Invest, with participation from existing seed investors Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), LoLa Capital Partners, and GordonMD Global Investments. The initial seed round was provided by a16z Bio+Health, Emerson Collective/Yosemite, and OMX. Total raised to date: $121 million (per PitchBook).
Clinical studies for lead candidate STP-100 are expected to begin in early 2027.
The company was founded in 2022 by Aaron Ring, MD, PhD (Associate Professor, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center) and Aashish Manglik, MD, PhD (Associate Professor, Pharmaceutical Chemistry, UCSF). CEO is Jeff Landau (previously CytomX Therapeutics).
The Pointillist platform identifies tumor-specific cell surface epitopes at single-epitope resolution — an "epitomics" approach that aims to go beyond gene-expression-level target identification to map post-translational modifications and conformational states unique to tumor cells.
Specific license terms from Fred Hutch and UCSF are entirely undisclosed — no public patent filings are yet visible. Fred Hutch's standard policy states that the institution and contributing scientists "may stand to benefit from future commercialization."
Reverse Merger: Korsana Biosciences / Cyclerion Therapeutics — $380 Million PIPE and Public Listing (April 1, Covered W15)
While announced on April 1, the Korsana Biosciences / Cyclerion Therapeutics reverse merger received its primary analyst and trade press coverage during the W15 window. Korsana, a privately held Alzheimer's-focused biotech, will merge into Cyclerion (NASDAQ: CYCN) in a transaction accompanied by a $380 million concurrent PIPE. Korsana's lead asset targets neuroinflammation in Alzheimer's disease. The combined entity will trade under a new ticker.
This is notable as one of the largest reverse merger PIPEs in recent biotech history and adds to the growing list of alternative public listing routes in 2026.
Industry: PhRMA CEO Steve Ubl to Step Down at Year-End (April 8)
PhRMA announced on April 8 that President and CEO Steve Ubl will depart at the end of 2026 after more than a decade as the trade group's longest-serving leader in its 68-year history. The departure comes at a challenging moment: PhRMA spent a record $38 million on lobbying in 2025, yet the White House has increasingly bypassed the trade association to negotiate directly with individual drugmakers on pricing commitments.
The board, chaired by Merck CEO Rob Davis, will conduct a search for Ubl's successor. The transition has implications for the industry's collective negotiating posture on tariffs, pricing reform, and regulatory policy heading into 2027.
Industry: TrumpRx Expansion — AbbVie, Genentech, Amgen Join Direct-to-Consumer Platform (April 6–8)
The White House's TrumpRx direct-to-consumer drug discount platform continued expanding during the W15 window, with three major pharma companies joining: AbbVie listed Humira at $950 (an ~86% discount from the >$6,900 list price), Genentech listed Xofluza at $50 (~70% discount), and Amgen added Enbrel and Otezla. The platform now lists 61+ medications.
TrumpRx participation is closely linked to the April 2 pharmaceutical tariff executive order, under which companies holding Most-Favored-Nation pricing deals receive full tariff exemptions (0% versus the default 100% tariff on patented pharmaceuticals effective July 31).
The interplay between TrumpRx participation, tariff exemptions, and onshoring commitments is rapidly reshaping the commercial economics of imported pharmaceuticals and has direct implications for royalty valuations on products with significant ex-U.S. manufacturing exposure.
Industry: Merck / Chongqing Zhifei — China Vaccine Distribution Terms Modified (Week of April 7)
Merck & Co. and Chongqing Zhifei Biological Products (SZSE: 300122) agreed to modify their China vaccine distribution arrangement covering Gardasil, RotaTeq, and Pneumovax 23 by removing minimum purchase commitments and transitioning to a rolling, demand-based supply model. The modification was disclosed via a Shenzhen Stock Exchange filing.
The shift from committed volumes to demand-based ordering reflects the challenging commercial environment for Gardasil in China, where domestic HPV vaccine competition (notably from Innovax's Cecolin and Walvax's 9-valent candidate) and evolving government immunization procurement practices have compressed Merck's market share. The change materially alters the economics of Zhifei's exclusive distribution relationship and may affect Merck's near-term China vaccine revenue recognition.
Industry: Sun Pharma / Organon — Reported $12 Billion Acquisition Bid (April 10)
On April 10, The Economic Times reported that Sun Pharmaceutical Industries (NSE: SUNPHARMA) is preparing a binding ~$12 billion all-cash offer for Organon & Co. (NYSE: OGN), up from a reported non-binding ~$10 billion offer submitted in January.
Three global banks — including JPMorgan and MUFG — are reportedly mandated for financing.
Organon shares surged approximately 27% on the news, while Sun Pharma fell ~3%. Sun Pharma formally told BSE and NSE the reports are "speculative" with no material event requiring disclosure.
If completed, this would be the largest overseas acquisition by an Indian pharmaceutical company, giving Sun Pharma a major women's health (Nexplanon), biosimilars (six marketed products), and established brands portfolio. Organon was spun out of Merck in June 2021 with approximately $9 billion in debt and generated ~$6.3 billion in 2025 revenue.
The deal remains unconfirmed but is market-moving and has significant royalty implications given Organon's extensive licensing arrangements on the Merck-originated portfolio.
Industry: Novo Nordisk Bloomington Layoffs and Restructuring Update (April 8)
Novo Nordisk cut approximately 400 jobs at its Bloomington, Indiana manufacturing facility — roughly one-fifth of the workforce at the former Catalent site that produces GLP-1 drug substance and drug product. The layoffs are part of Novo's broader global restructuring under new CEO Daniel Thuesen, targeting approximately 9,000 total job cuts and over $1.3 billion in annual savings by late 2026.
Combined with the Takeda U.S. restructuring (634 job cuts disclosed March 30) already noted in the Denali/Takeda termination section, large-pharma cost reduction remains a dominant industry theme.
Commercial Launch: Novo Nordisk — Wegovy HD (Semaglutide 7.2 mg) Available Nationwide (April 7)
On April 7, Novo Nordisk (NYSE: NVO) made Wegovy HD (semaglutide 7.2 mg) available nationwide through 70,000+ U.S. pharmacies, NovoCare Pharmacy, and select telehealth providers. Wegovy HD is the highest-dose semaglutide injection approved for chronic weight management, cleared March 19 via the FDA Commissioner's National Priority Review Voucher program.
| Term | Detail |
|---|---|
| Product | Wegovy HD (semaglutide injection 7.2 mg) |
| Indication | Chronic weight management in adults with obesity who have tolerated 2.4 mg for ≥4 weeks |
| Approval pathway | FDA National Priority Voucher (March 19, 2026) |
| Self-pay price | $399/month |
| Insured copay | As low as $25/month via savings card |
| Key trial | STEP UP: 20.7% mean weight loss at 72 weeks (efficacy estimand) vs. 17.5% on 2.4 mg and 2.4% on placebo |
| Manufacturing | Assembled and packaged at Novo Nordisk's Clayton, NC facility |
The pricing is strategically significant: at $399/month self-pay, Wegovy HD undercuts Eli Lilly's Zepbound ($449 cash-pay) while positioning above Lilly's Foundayo ($149/month oral). The launch creates a three-tier competitive landscape in the U.S. GLP-1 weight management market within a single week: oral small-molecule (Foundayo, $149), injectable standard-dose (Wegovy 2.4 mg, $349), and injectable high-dose (Wegovy HD, $399). Novo also announced a discounted subscription plan launched March 31 for self-pay patients.
Wegovy HD is already approved in the EU and UK at the 7.2 mg dose; regulatory decisions on a single-dose pen format are expected in H2 2026. Semaglutide was discovered and developed entirely in-house by Novo Nordisk; no third-party royalty obligations on Wegovy net sales have been identified. U.S. compound patent protection extends to approximately 2031–2032, with secondary formulation and method-of-use patents extending into the mid-2030s.
The Weekly Term Sheet is published by Capital for Cures AG via p05.org. Nothing in this publication constitutes investment advice. All royalty rate estimates are illustrative and based on publicly available disclosures.
Equity Raises: Forte Biosciences ~$150 Million Public Offering (April 8)
Forte Biosciences (NASDAQ: FTRE) priced an underwritten public offering on April 8 at $26.27 per share for gross proceeds of approximately $150 million (up to ~$162 million with full exercise of the underwriter's overallotment option). Joint bookrunners were Guggenheim Securities and Barclays. Net proceeds fund clinical development of FB102, an anti-CD122 (IL-2Rβ) monoclonal antibody in development for autoimmune indications including atopic dermatitis, with encouraging Phase 1 data in systemic sclerosis.
FB102 appears wholly proprietary — no upstream academic licenses or third-party in-licenses were disclosed across all reviewed 10-K filings (FY2020–FY2025). The patent portfolio comprises three pending PCT applications with estimated expiration in 2043–2045. The offering is among the larger biotech follow-ons of the week.
Equity Raises: Life Biosciences $80 Million Series D (April 8)
Life Biosciences (private, Boston) announced an $80 million fully subscribed Series D financing on April 8 to advance its lead program ER-100 (AAV-delivered OSK gene therapy) into Phase 1 clinical trials in optic neuropathies (open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy). The company's Partial Epigenetic Reprogramming (PER) platform aims to restore youthful gene expression in aged or diseased cells.
Life Biosciences was co-founded by David Sinclair, PhD (Harvard Medical School, Dept. of Genetics).
The core IP is Harvard's patent family WO2020069373A1 ("Cellular reprogramming to reverse aging and promote organ and tissue regeneration"), invented by Sinclair and Yuancheng Lu, with multiple granted U.S. patents including US 12,274,733. Harvard exclusively licensed this to Iduna Therapeutics (Life Bio subsidiary, merged in September 2021).
Harvard OTD's published template license structure includes earned royalties on net sales, sublicense income sharing, annual maintenance fees, and development milestones — actual rates are redacted but industry benchmarks for foundational gene therapy academic IP suggest 2–4% royalty on net sales and 15–30% of non-royalty sublicense income.
Life Biosciences also holds a separate license from Albert Einstein College of Medicine for chaperone-mediated autophagy (Ana Maria Cuervo lab), creating a dual-institution academic IP dependency.
Equity Raises: Celldex Therapeutics $345 Million Public Offering (April 6)
Celldex Therapeutics (NASDAQ: CLDX) priced a public equity offering on April 6, selling 11,896,750 shares (including full exercise of the 1,551,750-share overallotment option) at $29.00 per share, raising gross proceeds of approximately $345 million. Net proceeds after underwriting fees will fund pipeline development, primarily commercial readiness for barzolvolimab, an anti-KIT monoclonal antibody in Phase 3 for chronic spontaneous urticaria.
Joint bookrunning managers were Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor; co-lead managers were LifeSci Capital and H.C. Wainwright; legal opinion was provided by Lowenstein Sandler LLP. Barzolvolimab (CDX-0159) was discovered and developed entirely in-house by Celldex, with no disclosed upstream academic license obligations or third-party royalty encumbrances.
Licensing: Transgene / NEC Bio — AI Neoantigen Platform License for TG4050 (April 6)
On April 6, Transgene SA (Euronext: TNG) signed an exclusive license with NEC Bio B.V. (Netherlands/Japan) granting Transgene access to NEC's AI-driven neoantigen prediction platform for use in its personalized cancer vaccine program TG4050, targeting head and neck squamous cell carcinoma and other solid tumors.
Deal Structure
| Term | Detail |
|---|---|
| Licensor | NEC Bio B.V. (NEC Corporation subsidiary) |
| Licensee | Transgene SA (Euronext: TNG) |
| License scope | Exclusive use of NEC's AI neoantigen platform for TG4050 program |
| Upfront — shares | 3,345,824 new Transgene shares issued to NEC Bio at €0.7472 each (€2.5 million) |
| Upfront — cash | €2.5 million cash |
| Total upfront | €5.0 million |
| Milestones | Development, regulatory, and commercial milestones up to low triple-digit millions (USD) |
| Profit/sublicense share | Double-digit percentage of profits or sublicensing income |
| Platform ownership | NEC Bio retains full ownership; provides ongoing development support |
TG4050 is a Modified Vaccinia Ankara (MVA) viral vector-based personalized neoantigen vaccine individualized per patient using AI prediction of tumor-specific mutations, built on Transgene's proprietary myvac® platform. Phase 2 data in HPV-negative head and neck cancer are ongoing.
NEC Bio's AI neoantigen prediction platform is proprietary, built on 20+ years of NEC Corporation AI research augmented by the 2019 acquisition of OncoImmunity AS (Norwegian ML neoantigen prediction company) and the 2022 acquisition of VAXIMM AG neoantigen vaccine assets — no specific upstream academic license obligations were identified for NEC's AI system.
Transgene is a subsidiary of Institut Mérieux (~55% equity via TSGH SAS, with enhanced control via double voting rights, not Institut Pasteur) and holds its own extensive patent estate for MVA-based constructs; Mérieux's economic interest flows purely through equity ownership — no internal licensing or royalty arrangement was identified.
The double-digit profit share — rather than a conventional net sales royalty — is notable structure for an AI platform license in the personalized medicine space, and means any future Transgene sublicensing partner would face a significant downstream share flowing to NEC Bio.
Licensing: Halozyme / Vertex Pharmaceuticals — Hypercon Microparticle Technology (April 7)
On April 7, Halozyme Therapeutics (NASDAQ: HALO) announced a global exclusive collaboration and license agreement with Vertex Pharmaceuticals (NASDAQ: VRTX) for Halozyme's Hypercon™ microparticle technology across up to three drug targets.
Deal Structure
| Term | Detail |
|---|---|
| Licensor | Halozyme Therapeutics, Inc. (NASDAQ: HALO) |
| Licensee | Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) |
| Technology | Hypercon™ microparticle hyperconcentration platform |
| Scope | Up to three drug targets |
| Upfront payment | $15 million |
| Milestones | Development, regulatory, and commercial milestones (undisclosed aggregate) |
| Royalties | On net sales of products incorporating Hypercon technology |
Hypercon is a hyperconcentration technology that reduces injection volumes for biologics, enabling subcutaneous at-home administration of therapies that would otherwise require IV infusion. Halozyme acquired the platform through its November 2025 purchase of Elektrofi for $750 million cash upfront plus up to three $50 million contingent milestone payments (total up to $900 million), triggered by regulatory approvals of Hypercon-enabled products.
Elektrofi was co-founded by Chase Coffman (MIT PhD in electrohydrodynamic fluid mechanics); the technology was developed independently post-graduation and no formal MIT license agreement was identified. Vertex joins Janssen (~$800M deal, 5 programs), Eli Lilly ($470M, 3 targets), and argenx as Hypercon licensees.
The ENHANZE platform provides the best public benchmark for Hypercon royalty economics: Halozyme's SEC filings consistently disclose mid-single-digit royalty rates (~3–7%) across all ENHANZE licensees, and Halozyme has stated Hypercon follows the same licensing/royalty business model. The Hypercon patent suite extends into the 2040s.
For Halozyme, the deal extends the company's platform licensing model beyond ENHANZE into a second drug-delivery technology vertical, diversifying its royalty income stream.
Licensing: Dyno Therapeutics / Astellas Pharma — AAV Capsid Option-to-License (April 8)
On April 8, Dyno Therapeutics (private, Cambridge, MA) and Astellas Pharma (TSE: 4503) announced an option-to-license agreement granting Astellas the right to license Dyno-engineered AAV capsids for use across up to four therapeutic targets.
| Term | Detail |
|---|---|
| Licensor | Dyno Therapeutics, Inc. (private) |
| Licensee | Astellas Pharma Inc. (TSE: 4503) |
| Technology | Dyno CapsidMap™ engineered AAV vector capsids |
| Scope | Up to four drug targets |
| Initial option fee | $15 million |
| Milestones | Opt-in fees + development/regulatory/commercial milestones (undisclosed) |
| Royalties | On net sales of products incorporating Dyno capsids (rate not disclosed) |
| R&D funding | Astellas funds R&D during option periods |
Dyno's CapsidMap platform uses machine learning to design novel AAV capsids optimized for tissue-specific tropism, manufacturing yield, and immunogenicity evasion — addressing the key bottleneck in gene therapy delivery. The platform originated in George Church's lab at Harvard Medical School and the Wyss Institute, with key inventors including Eric Kelsic (CEO), Pierce Ogden, and Sam Sinai, drawing on foundational work published in Science (2019).
Dyno holds an exclusive option to enter into a license agreement with Harvard University; the specific Harvard OTD financial terms (royalty rates, milestones, equity stake) are not publicly disclosed given Dyno's private status.
This is Dyno's latest platform deal following collaborations with Novartis ($1.7 billion potential, 2021, ocular AAV), Roche/Spark ($1 billion+ potential, 2021, CNS — Roche exercised its first capsid option in January 2025 for a $7 million exercise fee and >$220 million in per-capsid milestones), Sarepta (>$40 million upfront, 2022, muscle-targeting), and Astellas itself (expanding a December 2021 relationship).
Across all five partnerships, specific royalty percentages have never been disclosed — only "royalties on net sales." The $15 million option fee matches the Halozyme/Vertex upfront announced the prior day, and the royalty-bearing structure positions Dyno as a recurring licensor of enabling gene therapy infrastructure.
Licensing: AC Immune / Eli Lilly — Morphomer Tau Collaboration Amendment ($12.5M Upfront) (April 7)
On April 7, AC Immune SA (NASDAQ: ACIU) announced an amendment to its December 2018 Tau aggregation inhibitor collaboration with Eli Lilly for Alzheimer's disease and other neurodegenerative tauopathies. Under the amended terms, AC Immune receives a CHF 10 million (~$12.5 million) upfront payment plus an additional Phase 1 dosing milestone. Total potential milestones remain above CHF 1.7 billion (~$2.1 billion) with low double-digit tiered royalties on net sales.
IND-enabling studies for new lead Tau Morphomer candidates are expected to commence in H1 2026. AC Immune's Morphomer platform generates small-molecule inhibitors of pathological protein aggregation; the Lilly collaboration targets Tau-specific conformations relevant to Alzheimer's and progressive supranuclear palsy.
Milestone: Nxera Pharma / Eli Lilly — Second Development Milestone for Metabolic GPCR Collaboration (April 9)
On April 9, Nxera Pharma (TSE: 4565) achieved its second development milestone under its multi-target GPCR-focused collaboration with Eli Lilly targeting diabetes and metabolic diseases, triggering an undisclosed payment. Nxera remains eligible for up to $694 million in total milestones plus tiered royalties on global net sales.
The collaboration leverages Nxera's proprietary NxWave structure-based drug design platform for GPCR targets. Two Lilly milestones in the same W15 window — alongside the AC Immune amendment — underscores Lilly's active management of its external innovation portfolio beyond the Foundayo launch.
Licensing: C4 Therapeutics / Roche — Degrader-Antibody Conjugate (DAC) Platform Collaboration (April 9)
On April 9, C4 Therapeutics (NASDAQ: CCCC) and Roche (SIX: ROG) announced a new multi-target research collaboration and license agreement focused on discovering and developing degrader-antibody conjugates (DACs) for oncology
— a novel modality combining targeted protein degradation payloads with antibody-directed delivery.
Deal Structure
| Term | Detail |
|---|---|
| Licensor | C4 Therapeutics, Inc. (NASDAQ: CCCC) |
| Licensee | Roche (SIX: ROG) / Genentech |
| Technology | C4T TORPEDO® targeted protein degradation platform |
| Scope | Initial two targets; option for third target |
| Upfront payment | $20 million |
| Option payment | Additional payment upon third-target opt-in |
| Near-term milestones | Discovery-stage milestones (undisclosed) |
| Total milestones | Eligible for over $1 billion |
| Royalties | Tiered royalties on net sales of products incorporating DAC technology |
| Development responsibility | Roche handles antibody design, conjugation, clinical development, and commercialization |
| C4T responsibility | Degrader payload design and optimization via TORPEDO® platform |
This expands an existing relationship — C4T and Roche have collaborated since 2021, initially on molecular glue degraders. The pivot to DACs is strategically significant: DACs represent a convergence of the ADC and TPD modalities, using an antibody to deliver a degrader payload directly to the tumor cell rather than a cytotoxic chemotherapy agent. If the approach works, it could offer a wider therapeutic window than conventional ADCs (which rely on cytotoxic payloads) and greater tissue specificity than systemic degraders.
The >$1 billion milestone package is among the largest announced for a degrader platform deal in 2026.
C4T's TORPEDO® platform is proprietary, developed from foundational research at Dana-Farber Cancer Institute in the laboratory of James "Jay" E. Bradner, MD (scientific co-founder, now President of NIBR at Novartis). Co-founders include Kenneth Anderson, MD, and Nathanael Gray, PhD (both Dana-Farber).
C4T exclusively licenses the Degronimid™ technology from Dana-Farber under a 2015 agreement covering all applications of targeted protein degradation; specific royalty rates under the Dana-Farber license are undisclosed but standard academic spinout terms (low single digits) are expected.
The new Roche DAC deal is structurally comparable to C4T's December 2023 Merck DAC collaboration, which disclosed more granular economics: Merck paid $10 million upfront with potential milestones of approximately $600 million per initial target (up to $2.5 billion across all options), plus royalties ranging from mid-single-digit to low-double-digit percent, subject to reductions under certain circumstances. The Roche deal's $20 million upfront (for two targets versus Merck's one) and >$1 billion milestone package suggest similar or slightly improved per-target economics.
Tiered royalties under the Roche deal are also subject to contractual reductions.
Upstream IP and Royalty Stack
| Layer | Direction | Recipient | Est. Rate |
|---|---|---|---|
| Dana-Farber Cancer Institute (Degronimid license) | Outflow from C4T / sublicense share | Dana-Farber | Low single-digit % (est.) |
| Roche tiered royalties (new, outflow to C4T) | Inflow to C4T from Roche | C4T | Mid-single to low-double digit % (est., per Merck DAC comparable) |
| Net C4T position | Positive — C4T receives net royalties after Dana-Farber sublicense share |
Collaboration: IDEAYA Biosciences / AstraZeneca — DLL3 ADC Clinical Trial Collaboration (April 8)
On April 8, IDEAYA Biosciences (NASDAQ: IDYA) entered a clinical trial collaboration and supply agreement with AstraZeneca (NASDAQ: AZN) to evaluate IDE849, a potential first-in-class DLL3-targeting topoisomerase-I inhibitor antibody-drug conjugate, in combination with AstraZeneca's Imfinzi (durvalumab).
| Term | Detail |
|---|---|
| Sponsor | IDEAYA Biosciences, Inc. (NASDAQ: IDYA) |
| Collaborator | AstraZeneca (NASDAQ: AZN) |
| Study drug | IDE849 (DLL3-directed Topo-I ADC) |
| Combination agent | Imfinzi (durvalumab, anti-PD-L1) |
| Indications | Extensive-stage small cell lung cancer (ES-SCLC); DLL3-upregulated solid tumors |
| Trial design | Global Phase 1 combination study |
| Financial terms | Not disclosed; AstraZeneca supplies Imfinzi at no cost; IDEAYA sponsors the trial |
IDE849 targets DLL3 (delta-like ligand 3), a surface protein selectively expressed on neuroendocrine tumors. The combination with Imfinzi tests the hypothesis that ADC-mediated tumor killing can synergize with checkpoint inhibition in SCLC, a disease where durvalumab (via CASPIAN) is already standard-of-care. This is a clinical supply agreement, not a licensing deal — IDEAYA retains full commercial rights to IDE849.
The material royalty obligation sits in IDEAYA's December 2024 license from Hengrui Pharmaceuticals (China) for IDE849 (originally SHR-4849): $75 million upfront, up to $200 million in development/regulatory milestones, up to $770 million in commercial milestones, and mid-single to low-double-digit royalties on net sales outside Greater China.
The DLL3 antibody and Topo-I payload are entirely Hengrui-proprietary — no upstream academic licenses were identified flowing through the Hengrui license.
Collaboration: Oxford BioTherapeutics / Bristol Myers Squibb — T-Cell Engager Discovery and Development for Solid Tumours (April 9)
On April 9, Oxford BioTherapeutics (OBT, private, Oxford/San Jose) announced a multi-year strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to discover and develop next-generation T-cell engager therapies for solid tumours.
| Term | Detail |
|---|---|
| Platform provider | Oxford BioTherapeutics (private) |
| Development/commercialization partner | Bristol Myers Squibb (NYSE: BMY) |
| Technology | OBT's proprietary OGAP®-Verify target discovery and validation platform |
| Scope | Multi-target; novel tumour-selective surface antigens for solid cancers |
| OBT responsibilities | Target identification, validation, and design and delivery of development candidates |
| BMS responsibilities | All subsequent research, clinical development, and global commercialization |
| Upfront | Upfront payment inclusive of research funding (amount not disclosed) |
| Milestones | Potential downstream milestone payments (not quantified) |
| Royalties | Royalties on net sales of commercialized products (rate not disclosed) |
This is OBT's third major pharma collaboration within 12 months, following prior deals with GSK and Roche — a pattern that validates the OGAP-Verify platform's commercial appeal. The collaboration is structurally notable: OBT goes beyond target identification to assume responsibility for designing and delivering development candidates, positioning the company as a fully integrated discovery-to-preclinical platform rather than a pure target-discovery licensor.
T-cell engagers for solid tumours remain one of the most active deal categories in oncology, with multiple large pharma companies (BMS, Roche, Amgen, Pfizer) competing to build pipelines in a space where clinical success has lagged behind hematologic indications.
Upstream IP and Royalty Stack
OBT was spun out of the University of Oxford's Department of Glyco Sciences in 2004, with the OGAP platform (Oxford Genome Anatomy Project) originating from academic proteomic research. Under Oxford University Innovation's standard spinout policies (historically ~20% equity to the university, dilutive), the University of Oxford almost certainly retains an equity interest in OBT that would benefit from any future exit or IPO.
Whether Oxford also holds a separate royalty interest on products arising from the OGAP platform IP — distinct from its equity stake — is not publicly confirmed given OBT's private status, but is consistent with OUI's licensing practices for foundational platform technologies.
OBT's existing partnership portfolio provides valuation context for the BMS deal: prior collaborations include Boehringer Ingelheim (multi-target discovery, with at least three options exercised and two compounds in clinical development), Genmab (IO antibody commercial license, October 2022, with upfront + milestones + royalties), GSK (2025), Roche (2025), and earlier collaborations with Kite Pharma (CAR-T), Amgen, ImmunoGen, and Medarex (BMS). Three programmes originating from the OGAP-Verify platform are currently in clinical development.
For each partner deal, OBT receives upfront payments, development/regulatory milestones, and royalties on net sales — creating a growing portfolio of downstream royalty interests that flow through to OBT's shareholders (including Oxford University).
Collaboration: Alloy Therapeutics / Biogen — AntiClastic ASO Platform License (April 7)
On April 7, Biogen (NASDAQ: BIIB) licensed access to Alloy Therapeutics' AntiClastic™ antisense oligonucleotide platform for multiple undisclosed therapeutic targets. Biogen paid an upfront fee plus milestone payments and tiered royalties on net sales. Terms were not fully disclosed, but the January 2025 Sanofi deal for a single CNS target provides a benchmark: up to $27.5 million upfront plus over $400 million in milestones and tiered royalties.
The AntiClastic platform uses transient cyclic (hairpin) structuring to achieve up to 50-fold potency improvement over conventional gapmers with enhanced tissue distribution.
The IP chain runs upstream from Arnay Sciences LLC, founded by antisense pioneer Dr. Sudhir Agrawal (400+ patents), which holds the foundational patent family (CA3174342A1, "Cyclic structured oligonucleotides as therapeutic agents," priority September 2021). Arnay exclusively licensed the platform to Alloy, which sublicenses to partners. Arnay Sciences almost certainly receives a sublicense pass-through from deals like Biogen and Sanofi, though specific terms are confidential. The technology was developed independently by Agrawal — no university license was identified.
Biogen separately disclosed approximately $34 million in Q1 2026 pre-tax IPR&D and milestone expenses via an April 6 8-K filing, indicating additional undisclosed deal activity.
Clinical: Insmed — Brensocatib Phase 2b CEDAR Failure in Hidradenitis Suppurativa (April 7)
On April 7, Insmed (NASDAQ: INSM) reported that its Phase 2b CEDAR trial of brensocatib (dipeptidyl peptidase 1 inhibitor) in moderate-to-severe hidradenitis suppurativa (HS) had failed all primary and secondary endpoints at both dose levels.
The placebo arm showed an unexpectedly strong 57.1% reduction in abscess and inflammatory nodule count at Week 16, compared to 45.5% for the 10 mg arm and 40.3% for the 40 mg arm — a numerically inverse dose-response that effectively buried any treatment signal.
Insmed will discontinue all HS development of brensocatib. This is the drug's second consecutive indication failure after the Phase 2 CRSsNP (chronic rhinosinusitis without nasal polyps) miss in December 2025. The commercially approved bronchiectasis indication (branded Brinsupri, approved June 2025, $173 million in 2025 net sales) is unaffected. The CEDAR failure reinforces the broader pattern of high placebo response rates confounding dermatology and inflammatory disease trials.
Brensocatib was originally developed by AstraZeneca (as AZD7986) and licensed to Insmed in October 2016 for $30 million upfront. The license agreement provides AstraZeneca with tiered royalties ranging from high single-digit to mid-teen percent on net sales, plus up to $85 million in development and regulatory milestones for the first indication and up to $42.5 million in additional milestones starting from Phase 3 initiation in a second indication. A further $35 million sales milestone is triggered at $1 billion in annual net sales.
AstraZeneca also retained an option (exercised March 2020) to negotiate commercialization rights in COPD or asthma. The foundational DPP1 inhibitor research traces to the University of Birmingham (UK), though specific academic royalty terms have not been publicly disclosed. The HS failure reduces the total addressable market for brensocatib and eliminates the second-indication milestone pathway.
The AstraZeneca license provides up to $42.5 million in additional milestones starting from Phase 3 initiation in a second indication — since CEDAR was a Phase 2b study and HS never advanced to Phase 3, this second-indication milestone tranche was not triggered and is now unlikely to be realized from HS.
The failure does not affect the bronchiectasis royalty stream — where AstraZeneca's high-single to mid-teen royalty on Brinsupri's $173 million in 2025 net sales already generates meaningful income.
Upstream IP and Royalty Stack
| Layer | Direction | Recipient | Est. Rate |
|---|---|---|---|
| AstraZeneca (originator license) | Outflow from Insmed | AstraZeneca (AZN) | High single-digit to mid-teen % (tiered) |
| University of Birmingham (foundational research) | Likely embedded in AZ-originated IP | Univ. Birmingham | Not separately disclosed |
| Total royalty burden on brensocatib net sales | ~8–15% (est.) |
Clinical: Sanofi — Lunsekimig Phase 2 Triple Readout: Respiratory Wins, Dermatology Miss (April 7)
On April 7, Sanofi (EPA: SAN) reported topline results from three Phase 2 studies of lunsekimig, a bispecific pentavalent Nanobody (VHH) that simultaneously blocks TSLP (upstream inflammation initiator) and IL-13 (downstream cytokine driving tissue damage) — a dual-targeting mechanism that Sanofi acquired through its 2018 acquisition of Ablynx.
| Study | Indication | Phase | Primary endpoint | Outcome |
|---|---|---|---|---|
| AIRCULES | Moderate-to-severe asthma | 2b | Annualized exacerbation rate reduction | Met (statistically significant, regardless of biomarker status) |
| DUET | Chronic rhinosinusitis with nasal polyps (CRSwNP) | 2a | Nasal polyp score change | Met (plus key secondary endpoints) |
| VELVET | Moderate-to-severe atopic dermatitis | 2b (exploratory) | EASI score % change | Missed (secondary endpoints EASI-75 and vIGA-AD 0/1 showed improvement) |
Lunsekimig was generally well tolerated across all three studies. Detailed results will be presented at upcoming medical congresses. The mixed profile — strong respiratory performance, weaker dermatology signal — has significant competitive implications: Jefferies analyst Michael Leuchten estimates $3 billion in peak annual sales for lunsekimig based on respiratory positioning alone.
The drug is one of three clinical-stage candidates Sanofi is developing as successors to its $18 billion/year Dupixent franchise (alongside amlitelimab and itepekimab) as patent protection approaches in the early 2030s. Phase 3 studies PERSEPHONE and THESEUS in COPD are ongoing; a Phase 2 in high-risk asthma (AIRLYMPUS) is also active. Lunsekimig originated from Ablynx's Nanobody platform — Sanofi acquired Ablynx for €3.9 billion in 2018.
No upstream academic royalties were identified; the Nanobody platform is wholly proprietary to the Sanofi/Ablynx inheritance.
Clinical: Amgen — Subcutaneous TEPEZZA Phase 3 Success in Thyroid Eye Disease (April 6)
On April 6, Amgen (NASDAQ: AMGN) reported positive topline Phase 3 results for subcutaneous TEPEZZA (teprotumumab) delivered via on-body injector in adults with moderate-to-severe active thyroid eye disease (TED).
| Endpoint | SC TEPEZZA | Placebo | p-value |
|---|---|---|---|
| Proptosis response (≥2mm reduction, Week 24) | 77.0% | 19.6% | <0.0001 |
| Mean proptosis reduction | -3.17 mm | -0.67 mm | <0.0001 |
| Diplopia response | Statistically significant | — | — |
| Clinical Activity Score response | Statistically significant | — | — |
TEPEZZA generated approximately $1.8 billion in 2025 net sales as an IV-only product requiring 60–90 minute infusions at infusion centers. The subcutaneous reformulation — a biweekly at-home injection via on-body injector — removes the infusion center bottleneck and could materially expand the addressable patient population. An sBLA filing is expected imminently with potential approval and launch in late 2026 or early 2027.
Amgen acquired TEPEZZA through its $27.8 billion acquisition of Horizon Therapeutics (closed October 2023). The underlying teprotumumab antibody was originally created by Genmab (NASDAQ: GMAB) using technology licensed from Medarex (now a wholly-owned BMS subsidiary) under a collaboration with Roche. Roche conducted initial oncology trials before returning rights; River Vision Development (later acquired by Horizon) repurposed the antibody for TED.
Under the terms of Genmab's original agreement with Roche, Genmab receives a mid-single-digit royalty on net sales of TEPEZZA — confirmed in Genmab's Q3 2025 interim report, which disclosed $75 million in TEPEZZA royalty revenue on $1,446 million in Amgen net sales during the first nine months of 2025 (implying an effective rate of approximately 5.2%).
The subcutaneous reformulation adds a second royalty layer: Amgen licensed Xeris Biopharma's (NASDAQ: XERS) proprietary XeriJect® technology in January 2024, under which Xeris is eligible for up to $75 million in development and regulatory milestones, plus sales-based milestones and escalating single-digit royalties on future SC TEPEZZA sales.
Xeris had already received a $6 million formulation success milestone in 2023; the positive Phase 3 readout on April 6 almost certainly triggers additional development milestones under the agreement, with regulatory milestones (sBLA acceptance, approval) to follow.
Upstream IP and Royalty Stack
| Layer | Direction | Recipient | Est. Rate |
|---|---|---|---|
| Genmab (antibody creator, via Roche sublicense) | Outflow from Amgen | Genmab (GMAB) | Mid-single digit % (~5.2% effective) |
| Xeris Biopharma (XeriJect SC formulation) | Outflow from Amgen (SC product only) | Xeris (XERS) | Escalating single-digit % |
| Medarex/BMS (transgenic mouse technology) | Likely embedded in Genmab-Roche terms | BMS (indirect) | Not separately disclosed |
| Total royalty burden on SC TEPEZZA net sales | ~7–12% (est.) (Genmab + Xeris combined) | ||
| Total royalty burden on IV TEPEZZA net sales | ~5% (Genmab only) |
Clinical: Organogenesis — PuraPly AM Diabetic Foot Ulcer RCT Positive (April 7)
On April 7, Organogenesis (NASDAQ: ORGO) reported that a 170-patient multicenter RCT of PuraPly AM (antimicrobial wound matrix) in diabetic foot ulcers achieved its primary endpoint of statistically significant complete wound closure at 12 weeks (p=0.0477). The stock surged approximately 20% on the data.
Separately, Organogenesis confirmed plans to file a rolling BLA for ReNu (amniotic suspension allograft for knee osteoarthritis) by December 2026.
Akari Therapeutics (NASDAQ: AKTX) and WuXi XDC (HKEX: 2268) announced a strategic R&D collaboration on April 6 to advance Akari's proprietary PH1 ADC payload AKTX-101, which targets RNA splicing in urothelial cancer. WuXi XDC will provide ADC development and manufacturing capabilities alongside Akari's payload biology. No financial terms — upfront payments, milestones, or royalties — were disclosed. This is a development and manufacturing alliance, not a licensed product deal.
Akari aims to accelerate an IND filing by late 2026 and begin a Phase 1 trial in late 2026 or early 2027. Beyond AKTX-101, Akari is also developing AKTX-102, a CEACAM5-targeting ADC using the same PH1 payload platform for multiple solid tumor types.
The PH1 payload is a novel Thailanstatin analog that modulates the spliceosome to disrupt RNA splicing in cancer cells. Three distinct Thailanstatin IP lineages exist and are legally separate: the foundational natural product was discovered by Yi-Qiang Cheng's group at the University of Wisconsin-Milwaukee (J. Nat. Prod. 2013); total synthesis was achieved by K.C. Nicolaou at Rice University (JACS 2016/2018), yielding US Patent 11,584,754 assigned to William Marsh Rice University.
However, Peak Bio's PH1 payload is covered by an independently developed patent family (US 10,301,319; US 10,815,246; US 11,691,982) with inventors Vasu Jammalamadaka, Sanjeev Satyal, and Hoyoung Huh, assigned to Ph Pharma Co Ltd — no co-assignee from UWM or Rice was identified. Akari acquired the PH1 platform through its November 2024 merger with Peak Bio, Inc. (approximately $39.2 million in recorded R&D value plus $8.4 million goodwill).
No upstream academic royalty obligations from the Peak Bio merger were found in public SEC filings, though freedom-to-operate overlap with Rice's derivative patents represents a potential risk. Akari's market capitalization of approximately $5–15 million raises questions about its capacity to navigate IP challenges independently.
Clinical: Corcept Therapeutics — ROSELLA Final Overall Survival Data at SGO 2026 with Lancet Publication (April 10)
On April 10, Corcept Therapeutics (NASDAQ: CORT) presented final overall survival data from the pivotal Phase 3 ROSELLA trial at the SGO 2026 Annual Meeting on Women's Cancer in San Juan, Puerto Rico, with simultaneous publication in The Lancet.
| Endpoint | Lifyorli + nab-paclitaxel (n=188) | Nab-paclitaxel alone (n=193) |
|---|---|---|
| Median overall survival | 16.0 months | 11.9 months |
| Hazard ratio (OS) | 0.65 (p=0.0004) | — |
| 12-month OS rate | 60% | 50% |
| 18-month OS rate | 46% | 27% |
| PFS (BICR, prior endpoint) | HR 0.70 (p=0.008) | — |
Lifyorli (relacorilant) is the first FDA-approved selective glucocorticoid receptor antagonist (SGRA). The ROSELLA trial is only the third trial ever to meet an overall survival endpoint in platinum-resistant ovarian cancer, alongside pivotal studies for bevacizumab and mirvetuximab soravtansine. Lifyorli received FDA approval in March 2026 and has been added to NCCN Guidelines as a preferred regimen.
OS benefits were consistent across all prespecified subgroups, including prior lines of therapy, PARP inhibitor exposure, and platinum-free interval length. The combination was well tolerated with no new safety signals — most adverse events were attributable to nab-paclitaxel rather than relacorilant.
Relacorilant is proprietary to Corcept, protected by composition-of-matter, method-of-use, and other patents, with orphan drug designations from both the FDA and the European Commission. An EMA Marketing Authorization Application is under review. Corcept generated $761 million in 2025 revenue (primarily from its Cushing's syndrome franchise) and guided 2026 revenue of $900 million–$1 billion.
The oncology launch of Lifyorli represents Corcept's first commercial entry beyond endocrinology and a potential step-change in the company's revenue trajectory.
Upstream IP and Royalty Stack
Relacorilant's composition-of-matter and core method-of-use patents are Corcept-owned. However, Corcept's 10-K filings (FY2022–FY2024) disclose an exclusive license from the University of Chicago covering patents for the use of cortisol modulators in the treatment of (a) triple-negative breast cancer and (b) castration-resistant prostate cancer. Corcept is required to pay the University of Chicago "customary milestone fees and royalties on revenue from products commercialized" under the licensed patents, which expire in 2031 and 2033.
The platinum-resistant ovarian cancer indication for Lifyorli is not explicitly covered by the University of Chicago license as publicly described — the license appears limited to TNBC and CRPC uses — but the presence of this academic license is notable for any future expansion of relacorilant into those indications.
The February 2026 Federal Circuit ruling against Corcept in the Teva/Korlym patent dispute (finding non-infringement of two method-of-use patents) does not directly affect the relacorilant patent estate, which is legally distinct from the mifepristone/Korlym IP.
| Layer | Direction | Recipient | Est. Rate |
|---|---|---|---|
| University of Chicago (TNBC/CRPC use patents) | Outflow from Corcept (if those indications commercialized) | University of Chicago | "Customary" (not quantified) |
| Core relacorilant composition/method-of-use | Corcept-owned | — | 0% |
| Total royalty burden on Lifyorli ovarian cancer net sales | 0% (current indication) |
Collaboration: Boehringer Ingelheim / BioNTech — DLL3 T-Cell Engager Plus PD-L1/VEGF-A Bispecific in SCLC (April 9)
On April 9, Boehringer Ingelheim announced a clinical trial collaboration and supply agreement with BioNTech SE (NASDAQ: BNTX) to evaluate a novel immunotherapy combination in extensive-stage small cell lung cancer (ES-SCLC).
| Term | Detail |
|---|---|
| Sponsor | Boehringer Ingelheim (regulatory sponsor) |
| Collaborator | BioNTech SE (NASDAQ: BNTX) |
| Study drug 1 | Obrixtamig (BI 764532, DLL3/CD3 T-cell engager) |
| Study drug 2 | Pumitamig (BNT327/BMS-986545, PD-L1/VEGF-A bispecific antibody; co-developed with Bristol Myers Squibb) |
| Indication | Extensive-stage small cell lung cancer (ES-SCLC) |
| Trial design | Phase Ib/II combination study |
| Financial terms | Not disclosed; BioNTech supplies pumitamig |
| Dosing expected | H2 2026 |
Obrixtamig achieved a 68% confirmed ORR, 89% disease control rate, and 52% 9-month PFS rate in the Phase I DAREON-8 first-line ES-SCLC study (in combination with chemotherapy and atezolizumab). A global Phase III trial (DAREON-Lung-1) is advancing. The collaboration combines two complementary immunotherapeutic mechanisms — DLL3-directed T-cell engagement and dual PD-L1/VEGF-A blockade — to explore more sustained tumor control in SCLC. Pumitamig is being jointly developed by BioNTech and Bristol Myers Squibb.
Both companies retain full rights to their respective assets under a mutually non-exclusive structure. Obrixtamig holds FDA Fast Track and Orphan Drug Designations, as well as EC Orphan Drug status for neuroendocrine carcinoma.
Notably, obrixtamig's DLL3 target was identified and validated by Oxford BioTherapeutics (OBT) — the same company that announced a new BMS T-cell engager collaboration during the W15 window. OBT has publicly announced multiple obrixtamig-related milestones, including the FDA Fast Track designations and first-patient-dosed events, confirming an active partnership interest.
The specific financial terms between OBT and Boehringer on obrixtamig are not publicly disclosed given OBT's private status, but OBT's OGAP-Verify target discovery platform — the same platform underlying the new BMS collaboration — is the source of the DLL3 target nomination. This means any obrixtamig commercial success would generate downstream royalty or milestone income flowing through OBT's existing Boehringer collaboration, adding a second major pharma revenue stream (alongside BMS) to OBT's platform economics.
Obrixtamig's core DLL3/CD3 bispecific antibody patents (WO2019234220A1) are assigned to Boehringer Ingelheim International GmbH, with no academic co-assignee identified.
Licensing: Click Therapeutics / Boehringer Ingelheim — $50 Million Series D and CT-155 Commercial Rights Transfer (April 9)
On April 9, Boehringer Ingelheim and Click Therapeutics (private, New York) announced a strategic agreement restructuring their long-standing collaboration on CT-155, an investigational prescription digital therapeutic for the experiential negative symptoms of schizophrenia.
| Term | Detail |
|---|---|
| Investor | Boehringer Ingelheim |
| Company | Click Therapeutics, Inc. (private) |
| Investment | $50 million Series D strategic investment |
| Additional funding | Dedicated commercial funding (undisclosed amount) |
| Rights transferred | Full product responsibility for CT-155, including all commercial and marketing authorization rights |
| Original collaboration | 2020 (valued at >$500 million) |
| CT-155 status | FDA Breakthrough Device designation; Phase 3 CONVOKE trial completed |
| Key Phase 3 result | 62% relative improvement in negative symptoms (p=0.0003) |
The restructuring is unusual: Boehringer developed CT-155 in collaboration with Click since 2020 but is now returning all commercial rights to Click while funding the transition via a $50 million strategic equity investment. Click now has three therapeutic programs with FDA authorization or Breakthrough designation: CT-155 (schizophrenia), Rejoyn (major depressive disorder, co-developed with Otsuka), and CT-132 (episodic migraine).
The deal positions Click as the most advanced prescription digital therapeutics company with commercial-stage assets — a novel modality category with no established royalty benchmarks. The original collaboration was valued at over $500 million in potential milestones; the restructured arrangement effectively converts Boehringer from a commercialization partner to a financial investor.
Milestone: Cue Biopharma / Boehringer Ingelheim — $7.5 Million Preclinical Milestone for B-Cell Depleter (April 9)
On April 9, Cue Biopharma (NASDAQ: CUE) disclosed that it had triggered a $7.5 million preclinical milestone payment from Boehringer Ingelheim under their April 2025 collaboration for bispecific B-cell depletion molecules. The milestone was triggered by Boehringer's selection of the first development candidate — CUE-501 — for lead optimization, with payment expected in May 2026.
The original collaboration included a $12 million upfront payment and up to approximately $345 million in development, regulatory, and commercial milestones, plus tiered royalties on net sales. Cue Biopharma's Immuno-STAT (Selective Targeting and Alteration of T cells) platform generates bispecific molecules that selectively engage T cells at disease-relevant sites; CUE-501 targets B-cell depletion without the broad immunosuppression associated with conventional anti-CD20 therapies.
Upstream IP and Royalty Stack
The Immuno-STAT (synTac) platform was invented by Dr. Steven C. Almo at Albert Einstein College of Medicine. The Einstein license (effective January 2015, amended through April 2025) creates one of the most quantifiable academic sublicense cascades in this week's term sheet: Einstein receives a low-to-high teens percentage of all upfront, milestone, and lump-sum payments from sublicensees (rate varies by development stage), plus up to $1.85 million in per-product milestones and $5.75 million in cumulative sales milestones.
Royalty duration is 15 years from first sale (direct) or 10 years (sublicensee). Einstein holds equity in Cue Biopharma. This means a quantifiable portion of the $12M upfront, the $7.5M milestone, and all future Boehringer payments will flow through to Einstein. Cue's IP portfolio encompasses approximately 300 pending applications and issued patents.
| Layer | Direction | Recipient | Est. Rate |
|---|---|---|---|
| Einstein College of Medicine (sublicense share) | Outflow from Cue | Einstein | Low-to-high teens % of all BI upfront/milestone payments |
| Einstein (direct sales royalty) | Outflow from Cue | Einstein | Low single-digit % |
| Einstein (per-product milestones) | Outflow from Cue | Einstein | Up to $1.85M per product |
| Total academic burden on BI collaboration income | ~10–19% of non-royalty income; low single digits on net sales |
Prior-Weekend Disclosure: Denali Therapeutics / Takeda — DNL593 Rights Revert; Royalty Pharma $200M Payment Triggered (April 3; RPRX Payment W15)
The termination was disclosed April 3 (Thursday before the W15 window). It is included here because the Royalty Pharma $200 million synthetic royalty payment — triggered by the March 25 FDA approval of AVLAYAH — was disbursed during the W15 window, and the DNL593 termination provides essential context for the TransportVehicle platform's royalty economics.
On April 3, Denali Therapeutics (NASDAQ: DNLI) disclosed that Takeda Pharmaceutical had provided written notice to terminate the January 2018 collaboration agreement to co-develop and co-commercialize DNL593 (PTV:PGRN), an investigational progranulin replacement therapy for GRN-related frontotemporal dementia (FTD-GRN).
The termination becomes effective approximately June 2, 2026 (60 days from notice).
Takeda cited strategic considerations unrelated to efficacy or safety data. All global development and commercialization rights and intellectual property revert to Denali at no cost; Denali owes no further payments to Takeda.
The original January 2018 collaboration involved a $150 million total commitment from Takeda: a $40 million upfront cash payment plus a $110 million equity investment in Denali. The deal covered up to three programs using Denali's TransportVehicle platform, with potential milestone payments of up to $630 million (clinical, regulatory, and sales-based) and 50/50 profit sharing post-opt-in. Takeda exercised its option on DNL593 and ATV:TREM2 in 2021, paying $10 million in option fees.
Since it is Takeda that terminated, the agreement contemplates a clean break with no residual economic interest in DNL593 for Takeda.
DNL593 uses Denali's proprietary TransportVehicle technology to deliver progranulin across the blood-brain barrier. Denali's Phase 1/2 study has 40 FTD-GRN patients fully enrolled, with results including biomarker data expected by end of 2026. Denali plans to continue clinical development independently. No approved disease-modifying therapies exist for FTD; active competitors in progranulin replacement include Passage Bio (PBFT02, AAV1 gene therapy), AviadoBio (AVB-101, AAV9), and Vesper Bio (VES001, oral sortilin inhibitor).
The TransportVehicle platform was validated by the March 25, 2026 FDA accelerated approval of AVLAYAH (tividenofusp alfa-eknm) for neurologic manifestations of Hunter syndrome (W13) — the first FDA-approved biologic designed to cross the blood-brain barrier. That approval satisfied the key closing condition of the Denali / Royalty Pharma $275 million synthetic royalty funding agreement (announced December 4, 2025; advised by Goodwin Procter for RPRX), triggering a $200 million initial payment from Royalty Pharma to Denali during the W15 window.
An additional $75 million is contingent on EMA approval by December 31, 2029. In exchange, Royalty Pharma receives a 9.25% royalty on worldwide net sales of tividenofusp alfa, capped at a 3.0× return (or 2.5× if achieved by Q1 2039). Denali retains all development and commercialization rights. The deal is one of the first synthetic royalty transactions anchored to a BBB-penetrant biologic and establishes a valuation benchmark for the emerging TransportVehicle asset class.
Denali was also awarded a Rare Pediatric Disease Priority Review Voucher in connection with the approval.
| Term | Detail |
|---|---|
| Collaboration partner | Takeda Pharmaceutical Company (TSE: 4502) |
| Company | Denali Therapeutics Inc. (NASDAQ: DNLI) |
| Original agreement date | January 2018 |
| Original Takeda commitment | $150 million ($40M upfront + $110M equity investment) |
| Option exercise | 2021 ($10M option fees for DNL593 and ATV:TREM2) |
| Potential milestones (original) | Up to $630 million (clinical + regulatory + sales) |
| Profit-sharing (original) | 50/50 post-opt-in |
| Termination notice | April 3, 2026 |
| Effective termination | ~June 2, 2026 (60 days) |
| Rights reverting | All global development, commercialization, and IP rights |
| Residual Takeda economic interest | None disclosed — clean break per press release; however, the original 2018 agreement contemplated that Takeda could negotiate royalties on Takeda-owned IP upon termination, creating limited ambiguity |
| Clinical status | Phase 1/2, 40 patients enrolled; data expected by end of 2026 |
The termination is notable in the broader context of Takeda's announced 634 U.S. job cuts (disclosed March 30) and ongoing restructuring under new CEO Julie Kim targeting over ¥200 billion ($1.26 billion) in annual savings.
Equity Raises: Adagene $70 Million ADS Offering Closes (April 6)
Adagene Inc. (NASDAQ: ADAG), a clinical-stage antibody engineering company based in San Diego and Suzhou, closed an underwritten public offering on April 6, selling 18,666,000 ADSs (each representing 1.25 ordinary shares) at $3.75 per ADS for gross proceeds of approximately $70 million. Joint book-runners were Leerink Partners and LifeSci Capital; co-manager was Lucid Capital Markets.
The company's lead clinical program is muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody with FDA Fast Track designation, currently in Phase 1b/2 and Phase 2 studies in combination with anti-PD-1 therapy for microsatellite-stable colorectal cancer (MSS CRC). Updated data (April 2, data cut January 24, 2026) showed a 33% overall response rate in MSS CRC patients without liver metastases at the 20 mg/kg loading dose.
Separately, Adagene announced a clinical collaboration with Incyte (April 2) to evaluate muzastotug + INCA33890 (TGFβR2×PD-1 bispecific) in MSS CRC, with the Phase 1 study expected to begin in 2026. Adagene also has a strategic collaboration with Sanofi evaluating ADG126 in combination with other anticancer therapies. The SAFEbody platform is proprietary to Adagene; no upstream academic royalties were identified.
Equity Raises: INOVIO Pharmaceuticals $17.5 Million Public Offering (April 2)
INOVIO Pharmaceuticals (NASDAQ: INO) priced an underwritten public offering on April 2, selling 12.5 million shares at $1.40 with accompanying Series A and Series B warrants (each exercisable for up to 12.5 million additional shares at $1.40). Gross proceeds of approximately $17.5 million. Sole manager: Piper Sandler.
The underwriter was granted a 30-day overallotment option for up to 1.875 million additional shares plus warrants.
IPO Filing: Avalyn Pharma Files S-1 for Nasdaq Listing (April 8)
Avalyn Pharma (proposed ticker: AVLN) filed its S-1 registration statement with the SEC on April 8, initiating a proposed Nasdaq IPO. Avalyn is a clinical-stage biopharmaceutical company developing inhaled formulations of approved oral medicines for life-threatening pulmonary diseases, with the goal of maximizing lung exposure while minimizing systemic side effects. No price range or share count was disclosed in the initial filing.
Morgan Stanley, Jefferies, Evercore ISI, and Guggenheim Securities are serving as joint bookrunning managers.
Pipeline
Avalyn's platform reformulates approved antifibrotic drugs — pirfenidone (Roche) and nintedanib (Boehringer Ingelheim) — for aerosolized lung delivery via the PARI eFlow® nebulizer. The lead program, AP01 (inhaled pirfenidone), is in a Phase 2b MIST trial in progressive pulmonary fibrosis (PPF), with clinical proof-of-concept established in the Phase 1b ATLAS study showing near-stabilization of lung function over 48 weeks and long-term safety and efficacy extending beyond 4.5 years in an open-label extension.
AP02 (inhaled nintedanib) completed Phase 1 SAD/MAD studies in IPF patients, demonstrating ~15-fold lower systemic Cmax and ~9-fold higher bronchoalveolar lavage exposure versus oral nintedanib. AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib — a combination not feasible orally due to additive side effects — is in IND-enabling studies.
Financing History and Investors
Avalyn has raised over $310 million in private capital: $35.5M Series B (2020, Norwest-led), $175M Series C (September 2023, Perceptive Xontogeny/SR One/Eventide-co-led), and $100M Series D (July 2025, Suvretta/SR One-co-led). Key institutional backers include Novo Holdings A/S, F-Prime Capital, Wellington Management, Catalio Capital Management, T. Rowe Price, Surveyor Capital (Citadel), Vida Ventures, and Rock Springs Capital.
Wilson Sonsini advised on the Series D.
Upstream IP and Royalty Context
Both pirfenidone and nintedanib are approved molecules; Avalyn's proprietary value rests in its inhaled formulations, nebulizer delivery optimization, and the clinical evidence base. All three programs use PARI Pharma GmbH's proprietary eFlow® nebulizer — a customized investigational device — confirming a license relationship, though specific royalty rates, milestones, and supply terms remain sealed within the S-1 (filed too recently for full EDGAR indexing).
On active-ingredient IP clearance: pirfenidone's composition-of-matter patents have expired, and Avalyn's aqueous nebulized formulation is distinct from Roche's oral Esbriet® — IP risk appears low. Nintedanib (Boehringer Ingelheim's Ofev®) presents higher risk, as composition patents may still be active and the 505(b)(2) pathway requires Paragraph IV certification against Orange Book-listed patents. Pulmonary fibrosis affects approximately 200,000 diagnosed patients in the U.S., with current oral therapies generating combined annual sales exceeding $5 billion (Ofev + Esbriet).
Avalyn's inhaled approach, if successful, could capture a significant share of patients who discontinue oral therapy due to tolerability issues.
Government Contract: Shionogi / BARDA — $119 Million Fetroja Preparedness and Manufacturing Award (April 8)
On April 8, Shionogi & Co., Ltd. (TSE: 4507) announced that its U.S. subsidiary Shionogi Inc. had been awarded a multi-year contract under Project BioShield from the Biomedical Advanced Research and Development Authority (BARDA) for Fetroja (cefiderocol), the siderophore cephalosporin antibiotic approved for complicated urinary tract infections and hospital-acquired/ventilator-associated bacterial pneumonia.
| Term | Detail |
|---|---|
| Contractor | Shionogi Inc. (U.S. subsidiary of Shionogi & Co., Ltd.) |
| Awarding agency | BARDA (Project BioShield) |
| Drug | Fetroja (cefiderocol) |
| Initial funding | $119 million |
| Multi-year options | Up to $482 million total |
| Scope | Establishment of a U.S. drug product manufacturing site, procurement of Fetroja stockpiles, development for certain biothreat pathogens, and pediatric HABP/VABP sNDA work |
The award is notable in the royalty and licensing context for two reasons: first, it provides non-dilutive government funding that de-risks the commercial economics of an antimicrobial asset — a category that has historically struggled with private-market return profiles; and second, the establishment of a dedicated U.S. manufacturing site for Fetroja strengthens the supply chain for potential future pull-incentive or strategic reserve programs.
Fetroja was originally discovered by Shionogi and has no disclosed upstream royalty obligations; it is one of the few novel-mechanism antibiotics launched in the last decade.
Government Contract: AVITA Medical / BARDA — $25.5 Million RECELL Burn Preparedness Agreement (April 8)
On April 8, AVITA Medical (NASDAQ: RCEL) announced a 10-year Project BioShield agreement with BARDA worth up to $25.5 million to bolster U.S. burn emergency preparedness using its RECELL® spray-on skin cell technology. BARDA will procure 3,000 RECELL units for the Strategic National Stockpile, with approximately $3.97 million in annual access-maintenance fees. RECELL uses a patient's own skin cells to generate a spray-on suspension for treating acute thermal burns, reducing the need for donor skin grafts.
The device holds FDA approval and a CE mark. This is the second BARDA contract announced during the W15 window, alongside the Shionogi/Fetroja award — reflecting continued government investment in medical countermeasure preparedness.
Regulatory: Immedica Pharma — Priority Review Voucher Issued for LOARGYS (April 7)
On April 7, the FDA published a Federal Register notice confirming the issuance of a Rare Pediatric Disease Priority Review Voucher to Immedica Pharma for LOARGYS (pegzilarginase-nbln), approved February 23, 2026, for the treatment of hyperargininemia in patients with Arginase 1 Deficiency. PRVs have traded at $100–$205 million in recent transactions (Fortress/Cyprium sold one for $205M in W14).
Immedica, a privately held Swedish specialty pharma company focused on rare diseases, could monetize this voucher through a sale — adding to a growing supply of PRVs that may exert downward pricing pressure in H2 2026. LOARGYS was developed by Aeglea BioTherapeutics (acquired by Immedica in 2023).
Regulatory: FDA Approves First Generic Dapagliflozin (Farxiga) (April 7)
On April 7, the FDA approved the first generic versions of dapagliflozin tablets (AstraZeneca's Farxiga), a landmark affordability milestone for the SGLT2 inhibitor class. Dapagliflozin is approved for type 2 diabetes, heart failure, and chronic kidney disease, with Farxiga generating approximately $7.7 billion in 2025 global sales for AstraZeneca. The generic approval affects an estimated 40+ million U.S. diabetes patients and will accelerate price erosion on AstraZeneca's branded franchise. Apotex received tentative approval for a related generic formulation on April 10.
The royalty context here is notable for what is absent: Bristol-Myers Squibb's sales-related royalty payments from AstraZeneca on dapagliflozin — established when BMS sold its diabetes business to AstraZeneca for $2.7 billion upfront in February 2014 — expired at the end of 2025 per the original agreement terms. As a result, AstraZeneca faces generic erosion on a now royalty-unencumbered product.
Regulatory: Biocon U.S. Commercial Launch of Denosumab Biosimilars (April 7–8)
Biocon (BSE: 532523) commercially launched Bosaya (denosumab-kyqq, biosimilar to Prolia) and Aukelso (denosumab-kyqq, biosimilar to Xgeva) in the United States on April 7–8, marking the first India-based company to launch interchangeable denosumab biosimilars in the U.S. market. Prolia and Xgeva together generated approximately $5 billion in 2025 global sales for Amgen.
The biosimilar launches intensify competition in the denosumab franchise and add to the growing erosion pressure on Amgen's mature biologics portfolio — notable in the same week that Amgen reported positive SC TEPEZZA Phase 3 data for its growth franchise.
Regulatory: GSK Wellcovorin NDA Withdrawal (April 9–10)
The FDA published a Federal Register notice on April 10 confirming the withdrawal of GSK's NDA for Wellcovorin (leucovorin calcium tablets) at GSK's request — the company no longer markets or manufactures the product.
The withdrawal is politically notable: Wellcovorin was re-approved just months earlier (September 2025) for cerebral folate deficiency at the FDA's initiative, linked to the administration's promotion of leucovorin as a potential autism treatment. Generic leucovorin remains available.
Other: Scinai Immunotherapeutics — CDMO Subsidiary Reorganization (April 6)
Scinai Immunotherapeutics (NASDAQ: SCNI) completed an internal corporate reorganization on April 6, establishing Scinai Biopharma Services Ltd. as a dedicated wholly owned CDMO subsidiary following its February 2026 acquisition of Recipharm Israel. The new unit absorbs the manufacturing services business and the referral-based royalty streams that were part of the Recipharm deal. Scinai Biopharma Services targets approximately $5 million in CDMO revenue in 2026.
No external transaction or new capital raise was involved.
Clinical: Praxis Precision Medicines — Elsunersen Phase 1/2 Data in SCN2A Epilepsy (April 6)
Praxis Precision Medicines (NASDAQ: PRAX) reported positive topline results on April 6 from EMBRAVE Part A, a randomized, placebo-controlled Phase 1/2 trial of elsunersen (PRAX-222), an antisense oligonucleotide, in pediatric patients (ages 2–12) with early-seizure-onset SCN2A developmental and epileptic encephalopathy (DEE).
Key results: 77% placebo-adjusted seizure reduction from baseline (p=0.015), with 71% of treated patients achieving greater than 50% seizure reduction and 57% experiencing at least a 28-day seizure-free period. All elsunersen patients showed improvements in sleep, motor function, muscle tone, or attention versus zero on placebo. No drug-related serious adverse events were reported, and efficacy sustained in open-label extension for up to one year.
This bolsters Praxis's neuroscience franchise alongside its filed NDAs for ulixacaltamide (essential tremor) and relutrigine (SCN2A/SCN8A DEEs, PDUFA September 27, 2026).
Upstream IP and Royalty Stack
Elsunersen was not developed purely in-house. The program originated from a Research Collaboration, Option and License Agreement between Praxis and Ionis Pharmaceuticals (NASDAQ: IONS), under which Ionis conducted the initial drug discovery to identify elsunersen as a development candidate and completed IND-enabling toxicology studies. Praxis exercised its option to license exclusive worldwide development and commercialization rights.
RogCon, Inc. initially identified the opportunity with Ionis and contributed foundational patent rights and know-how.
Per Praxis's 10-K filings, the royalty obligations on elsunersen are substantial:
| Layer | Direction | Recipient | Rate / Terms |
|---|---|---|---|
| Ionis Pharmaceuticals | Outflow from Praxis | Ionis (NASDAQ: IONS) | Royalties in the low-20s% on net sales worldwide; sublicense fees in the low-to-mid double digits%; $5M development milestones per product; $5M additional milestone + interest |
| RogCon, Inc. | Outflow from Praxis | RogCon | Mid-teens% profit share on net profits; $3M one-time milestone |
| Total royalty/profit-share burden | ~35–40% effective burden (Ionis royalty + RogCon profit share are overlapping, not additive at face value, but combined drag is among the heaviest in this week's term sheet) |
The Ionis royalty is particularly notable because Ionis itself has monetized portions of its royalty portfolio through Royalty Pharma (RPRX) — though the RPRX/Ionis deal specifically covered Spinraza and pelacarsen, not the Praxis collaboration assets. The positive EMBRAVE Part A results on April 6 — showing 77% placebo-adjusted seizure reduction — may trigger one of the $5 million development milestones payable to Ionis, depending on the specific milestone definitions in the agreement (clinical data readouts, IND filings, or Phase 2/3 initiation).
If elsunersen reaches commercialization, Ionis's royalty interest could become a future monetization candidate given RPRX's established relationship with Ionis.
Regulatory: Ascendis Pharma YUVIWEL Orphan Exclusivity, PRV, and Commercial Launch (April 6)
On April 6, the FDA granted orphan drug exclusivity to Ascendis Pharma's (NASDAQ: ASND) YUVIWEL (navepegritide/TransCon CNP), extending exclusivity to approximately 2033. YUVIWEL is the first and only once-weekly treatment approved for children aged 2 and older with achondroplasia, and is now commercially available in the United States.
The February 2026 accelerated approval also triggered a Rare Pediatric Disease Priority Review Voucher (PRV) — a monetizable asset that recent transactions have valued at $100–205 million (Fortress/Cyprium sold a PRV for $205 million in W14) and that Ascendis could sell, retain for internal use, or trade. YUVIWEL is Ascendis's third FDA-approved TransCon product. The PRV issuance was noted in W14; the orphan exclusivity grant and commercial launch are new to W15.
Upstream IP and Royalty Stack
Ascendis's 20-F is explicit: "we owe no third-party royalty or milestone payment obligations with respect to our TransCon technologies" or any product candidates, other than the Royalty Pharma synthetic royalty arrangements. The TransCon platform is entirely proprietary to Ascendis.
Critically, while YUVIWEL itself does not yet carry a Royalty Pharma royalty, Ascendis's two other TransCon products do:
| Product | RPRX Royalty | Upfront | Date |
|---|---|---|---|
| SKYTROFA (TransCon hGH) | 9.15% on U.S. net sales | $150 million | September 2023 |
| YORVIPATH (TransCon PTH) | 3.0% on U.S. net sales | $150 million | September 2024 |
| YUVIWEL (TransCon CNP) | None yet | — | — |
The pattern of sequential RPRX synthetic royalty deals on each new TransCon product at launch makes YUVIWEL a natural candidate for a future monetization. Achondroplasia affects ~250,000 people worldwide and YUVIWEL's orphan exclusivity through 2033 provides a durable revenue runway.
CFO Rob Smith has indicated Ascendis is "likely to sell the PRV" given that many Ascendis products already receive priority reviews; analysts estimate a sale price of approximately $200 million based on the Fortress/Cyprium $205M PRV precedent from W14.
| Layer | Direction | Recipient | Rate |
|---|---|---|---|
| Third-party academic/platform | None | — | 0% |
| RPRX synthetic royalty | None (yet) | — | 0% |
| Total royalty burden on YUVIWEL net sales | 0% |
Clinical: Zentalis Pharmaceuticals — Azenosertib Pivotal Dose Selection in Ovarian Cancer (April 9)
On April 9, Zentalis Pharmaceuticals (NASDAQ: ZNTL) announced pivotal dose selection for azenosertib, a potential first-in-class WEE1 inhibitor, based on a prespecified interim analysis from the DENALI Part 2a trial.
The 400mg QD 5:2 schedule (five days on, two days off) was selected as the pivotal monotherapy dose in Cyclin E1-positive platinum-resistant ovarian cancer, showing a clearly differentiated response rate over the 300mg dose with a comparable safety profile. Integrated data at the 400mg dose showed an ORR exceeding 30% with a median duration of response of approximately 5–6 months. The DENALI Part 2 topline readout (designed to support accelerated approval) is expected by year-end 2026, with the confirmatory Phase 3 ASPENOVA trial (~420 patients) initiating Q2 2026.
The dose selection is notable in the context of two other platinum-resistant ovarian cancer data readouts during the W15 window: Corcept's positive ROSELLA OS data for Lifyorli and the SGO meeting's broader focus on the indication.
Upstream IP and Royalty Stack
Azenosertib (originally ZN-c3) is exclusively licensed from Recurium IP Holdings, LLC (f/k/a Zeno Royalties & Milestones, LLC) under a license agreement first executed in 2019 and amended multiple times through June 2023. Per Zentalis's 10-K, the company's subsidiary ZMI is obligated to pay Recurium development and regulatory milestone payments with respect to azenosertib; specific rates are redacted in public filings.
In June 2023, Zentalis terminated its Greater China sublicense with Zentera Therapeutics, paying Zentera $30 million upfront, a milestone payment, and agreeing to a low single-digit royalty on net sales of azenosertib in Greater China — regaining worldwide rights. The Recurium license covers the foundational intellectual property for azenosertib, and any royalty obligations to Recurium on worldwide net sales would sit upstream of any commercialization economics.
Zentalis now holds worldwide development and commercialization rights to azenosertib following the Zentera termination.
| Layer | Direction | Recipient | Est. Rate |
|---|---|---|---|
| Recurium IP Holdings (foundational license) | Outflow from Zentalis | Recurium | Milestones + royalties (rates redacted) |
| Zentera Therapeutics (Greater China buyback) | Outflow from Zentalis (China only) | Zentera | Low single-digit % on Greater China net sales |
| Total royalty burden on azenosertib net sales (ex-China) | Recurium obligations only (rates undisclosed) |
Regulatory: Replimune RP1 Receives Second FDA Complete Response Letter (April 10)
On April 10, the FDA issued a second Complete Response Letter (CRL) to Replimune Group (NASDAQ: REPL), denying approval for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma — citing insufficient evidence of effectiveness despite the drug's Breakthrough Therapy designation.
In the IGNYTE trial, RP1 plus nivolumab demonstrated a 34% response rate with a median duration of response of 24.8 months and median PFS of 30.6 months (versus 4.4 months on prior PD-1 therapy) in patients with confirmed progression on an anti-PD-1 regimen.
The rejection has far-reaching consequences. Replimune CEO Sushil Patel stated that without timely accelerated approval, RP1 development "will not be viable" — the company announced immediate job eliminations and a substantial scale-back of U.S. manufacturing operations. The decision follows the July 2025 first CRL, which was attributed to intervention by then-CDER head Richard Pazdur (who overruled consensus at CBER) and CBER chief Vinay Prasad (who deferred to Pazdur).
Despite Prasad's announced departure by end of April 2026 and an open letter from nearly two dozen melanoma investigators supporting RP1, the FDA maintained that longstanding study design concerns communicated since 2021 were not adequately addressed. The agency recommended Replimune consider using data from its ongoing Phase 3 IGNYTE-3 trial to support a future accelerated approval filing. Replimune shares fell approximately 20% on the news.
The decision is being viewed as a bellwether for the FDA's regulatory posture on single-arm oncology trials under current leadership.
RP1 is a next-generation HSV-1-based oncolytic immunotherapy built on Replimune's proprietary RPx platform. The company was founded in 2015 by Robert Coffin, PhD, who previously founded BioVex (spun out of his research group at University College London in 1999, acquired by Amgen for up to $1 billion in 2011, yielding T-VEC/Imlygic).
Critically, Replimune's RPx platform and RP1 are not derived from the BioVex/UCL intellectual property — Coffin developed a new proprietary HSV-1 strain (RH018), entirely different from BioVex's JS1 strain, and the differentiating GALV-GP R(-) fusogenic protein is Replimune's proprietary innovation.
The core RP1 patents (six PCT families filed January 2016, including WO2017/118864, "Modified oncolytic virus") are assigned to Replimune Ltd with Coffin as inventor, yielding six U.S., four European, and four Japanese granted patents with protection extending to approximately 2037 (potentially extendable via Hatch-Waxman PTE). No upstream academic license obligations or third-party royalties were identified across all reviewed SEC filings — making RP1 one of the cleanest royalty profiles in this week's term sheet.
Bristol-Myers Squibb provides nivolumab at no cost under a royalty-free, non-exclusive Clinical Trial Collaboration and Supply Agreement (effective February 2018) — nivolumab would be prescribed separately as BMS's own product post-approval, with no royalty, profit share, co-promotion, or other economic interest in RP1.
Prior-Week Deal Update: Merck / Terns Pharmaceuticals — Tender Offer Commenced, Negotiation Backstory Disclosed (April 7)
This is not a new W15 transaction. The definitive agreement was announced March 25 (W13) and covered in that issue. This section covers the April 7 tender offer commencement and the negotiation history disclosed in the SC TO-T and SC 14D-9 filings.
On April 7, Merck (NYSE: MRK) formally commenced a cash tender offer through its subsidiary Thailand Merger Sub, Inc. to acquire all outstanding shares of Terns Pharmaceuticals (NASDAQ: TERN) at $53.00 per share in cash, pursuant to the March 24 merger agreement.
The tender offer expires one minute after 11:59 p.m. Eastern Time on May 4, 2026, unless extended.
Negotiation Backstory (from SC TO-T / SC 14D-9)
The proxy filings disclosed a competitive process that materially altered the final price:
- Early February 2026: Merck submitted an initial proposal of $61.00 per share. Simultaneously, an unnamed "large pharmaceutical company" submitted a competing acquisition offer at $58.00 per share, later raised to $61.00.
- Mid-February: Terns provided both suitors with updated clinical data from the Phase 1 CARDINAL study of TERN-701 (oral allosteric TKI for chronic myeloid leukemia). The filing disclosed that the major molecular response (MMR) achievement rate was lower than the 64% rate presented at ASH in December 2025.
- Post-data review: Merck reduced its proposed purchase price to $50.00 per share, reflecting its revised assessment of the CARDINAL data.
- Final negotiation: The parties settled on $53.00 per share, representing approximately $6.7 billion in aggregate equity value.
Leerink Partners, advising Terns, concurred with Merck's downward reassessment. The competing bidder's final disposition was not disclosed. Terns CEO Mark Bhatt stated the transaction is expected to close later in Q2 2026.
The negotiation backstory is notable for the royalty and licensing community: it illustrates how mid-process clinical data updates — even incremental changes in a single biomarker endpoint — can move headline deal values by $1 billion or more in the current M&A environment, and underscores the importance of data-contingent pricing mechanisms (CVRs, milestone-linked payments) in bridging buyer-seller valuation gaps.
Equity Raises: Beacon Biosignals Series B Extension to $97 Million (April 6)
Beacon Biosignals (private, Boston) announced on April 6 that it had upsized its Series B from the original $86 million (November 2025) to over $97 million, bringing cumulative funding above $132 million.
New investors in the extension include JSL Health, Palo Santo VC, Kicker Ventures, and Samsung Next, joining original backers Innoviva, GV (Google Ventures), S32, Catalio Capital Management, General Catalyst, Logos Capital, Casdin Capital, and Indicator Ventures. Beacon's Waveband wearable EEG device (formerly Dreem 3S) holds FDA clearance; the capital accelerates its scalable at-home brain health monitoring and clinical trial support platform.
Equity Raises: Sidewinder Therapeutics $137 Million Series B (April 8)
Sidewinder Therapeutics (private, San Diego) announced an oversubscribed $137 million Series B on April 8 to advance its bispecific ADC pipeline into clinical development.
The round was co-led by Frazier Life Sciences and Novartis Venture Fund, with participation from the sole Series A investor OrbiMed, as well as new investors Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management, and Alexandria Venture Investments. Legal counsel: Wilson Sonsini (led by Lance Brady and Matthew Bresnahan). Total raised since 2023 founding: $162 million.
Sidewinder was co-founded by Eric Murphy (CEO, previously co-founded Kinnate Biopharma, acquired by XOMA in 2024, and led Alterome Therapeutics to $232M total funding) and Ryan Corcoran (Director of MGH's Gastrointestinal Cancer Center). President Robert McRae adds operational depth from public biotechs including Palisade Bio. Lead asset SWT012 targets bladder cancer with an IND filing targeted by end of 2026; additional programs target squamous cell carcinomas (lung, head and neck) and gastrointestinal cancers (colorectal).
The bispecific ADC approach — combining two distinct antigen-binding domains with a single cytotoxic payload — aims to improve tumor selectivity and reduce off-target toxicity compared to conventional monospecific ADCs. The platform leverages a partnership with Synaffix for linker-payload technology.
Equity Raises: Oricell Therapeutics $110 Million Pre-IPO (April 9)
Oricell Therapeutics (private, Shanghai) closed an oversubscribed $110 million pre-IPO round on April 9 to accelerate global development of its solid tumor CAR-T therapies.
The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners (an early investor since the Pre-A round), and a leading unnamed global healthcare fund. The syndicate also included an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital. Oricell previously raised a $70 million Series C1 in January 2026.
Lead asset Ori-C101 is a GPC3-targeted autologous CAR-T therapy for advanced hepatocellular carcinoma (HCC), with ASCO-presented Phase 1 data showing best-in-class efficacy and safety. Pivotal trials are expected imminently. The company's proprietary technology triad — Ori®Ab (antibody discovery), Ori®Armoring (T-cell enhancement), and OnGo (rapid manufacturing) — positions it across autologous, secreted, rapid-production, and in vivo CAR-T modalities. A second core candidate, OriCAR-017, holds both FDA and NMPA IND approvals plus FDA Orphan Drug and Fast Track Designations. CEO **Dr.
Huanfeng Yang** leads the company.
Equity Raises: Vivatides Therapeutics $54 Million Series A (April 10)
Vivatides Therapeutics (private, Suzhou/Boston) announced an oversubscribed $54 million Series A on April 10 to advance siRNA and antisense oligonucleotide therapies using a proprietary extrahepatic delivery platform into clinical development.
The round was co-led by Qiming Venture Partners and a leading industry fund, with participation from Highlight Capital, TF Capital, and existing investor Apricot Capital.
Equity Raises: Endovascular Engineering (E2) $80 Million Series C (April 7)
Endovascular Engineering (E2, private, commercial-stage medtech) raised an oversubscribed $80 million Series C on April 7, co-led by Gilde Healthcare and Norwest, with participation from Santé Ventures, 415 Capital, and undisclosed strategic investors. Total raised: $122 million across four rounds.
The capital advances E2's Hēlo Thrombectomy Platform for pulmonary embolism — a dual-action aspiration and mechanical clot disruption system that received FDA clearance in December 2025.
Equity Raises: Oncolytics Biotech $75 Million ATM Program (April 6)
Oncolytics Biotech (NASDAQ: ONCY) filed an 8-K on April 6 disclosing an Open Market Sale Agreement with Jefferies LLC enabling at-the-market sales of up to $75 million in common stock under its newly effective Form S-3 shelf registration. Jefferies receives up to a 3% commission.
Net proceeds fund clinical development of pelareorep, a first-in-class intravenously delivered double-stranded RNA immunotherapeutic agent (non-genetically modified reovirus isolate) with FDA Fast Track designations for metastatic breast cancer (2017), metastatic pancreatic ductal adenocarcinoma (2022), and colorectal cancer.
The same day, Oncolytics disclosed a Type C FDA meeting (scheduled April 16) to discuss a single-arm registrational pathway for pelareorep in second-line squamous cell anal cancer (SCAC), where GOBLET Cohort 4 data showed a 30% ORR and 15.5-month median duration of response in combination with atezolizumab.
Pelareorep originated from preclinical research at the University of Calgary by Patrick Lee, Jim Strong, and Matt Coffey (Oncolytics' co-founder) on the oncolytic potential of reovirus in the 1990s. The company was founded in 1998 to commercialize these discoveries.
Unlike a standard university license, Oncolytics' royalty obligations are structured as founding shareholder payment obligations — five founding shareholders (including University Technologies International Inc., Calgary's technology transfer arm) receive 10.75% of all licensing and partnership income (reduced from 20% through 2003–2004 amendments). Upon commercialization, this converts to 2.15% of net sales (reduced from 4%) plus a $1.0 million milestone within 90 days of first marketing approval.
These are among the most precisely disclosed academic-origin royalty rates of any deal in this week's term sheet. Oncolytics' patent portfolio spans approximately 137–242 patents globally, with protection extending to at least 2031 and a new Track 1 manufacturing patent application that could extend to 2044.
Other: Anthropic / Coefficient Bio — $400 Million AI-Biotech Acquisition (Reported April 2–3, Covered April 6)
While first reported by The Information and TechCrunch on April 2–3, the Anthropic acquisition of stealth AI-biotech startup Coefficient Bio for approximately $400 million in stock received its primary biopharma trade press coverage on April 6 via BioSpace, FierceBiotech, and Endpoints News. Coefficient Bio was a New York-based startup (fewer than 10 employees, approximately 8 months old) founded by former Genentech Prescient Design researchers Nathan C.
Frey and Samuel Stanton, with CEO Aris Theologis (ex-Evozyne/Paragon Biosciences). The team joins Anthropic's Healthcare and Life Sciences division, building on Claude for Life Sciences (launched October 2025) and Claude for Healthcare (January 2026). While primarily a tech deal without direct pharmaceutical royalty implications, it represents AI's largest direct entry into life sciences to date and signals accelerating convergence between AI platforms and drug discovery infrastructure.
Acquisition: Everest Medicines / Hasten Biopharmaceuticals — $250 Million APAC Platform Deal (April 8)
On April 8, Everest Medicines (HKEX: 1952.HK) announced that its wholly-owned subsidiary EverSea Medicines (Singapore) has entered into a Share Purchase Agreement with Hasten Biopharmaceuticals (Asia) Limited to conditionally acquire the entire equity interest in **Hasten Biopharmaceuticals (SG) Pte.
Ltd.** for an aggregate consideration of $250 million, payable in three installments.
Deal Structure
| Term | Detail |
|---|---|
| Acquirer | EverSea Medicines (Singapore) Pte. Ltd. (Everest Medicines subsidiary) |
| Target | Hasten Biopharmaceuticals (SG) Pte. Ltd. |
| Seller | Hasten Biopharmaceuticals (Asia) Limited |
| Consideration | $250 million (three installments) |
| Assets acquired | Ready-built Asia-Pacific commercial platform with 14 marketed chronic disease products |
| Target 2025 revenue | $82.2 million (normalized) |
| Target 2025 EBITDA | $27.3 million |
The acquisition accelerates Everest's Asia-Pacific expansion by delivering a pre-built regional commercial platform with 14 marketed products across chronic disease areas and near-term revenue and profitability. Everest positions the deal as strengthening its role as a regional partner of choice for both Chinese and global innovative assets.
Fund Close: Jeito Capital — Jeito II Final Close at $1.2 Billion (Announced April 7)
On April 7, Jeito Capital, the Paris-based independent private equity fund dedicated to biopharma, announced the final closing of Jeito II at $1.2 billion (above €1 billion), exceeding its fundraising target.
This is the largest raise ever achieved by a fully independent European fund dedicated to biopharma.
| Term | Detail |
|---|---|
| Fund | Jeito II |
| Final close | $1.2 billion (~€1 billion) |
| Close date | March 31, 2026 (announced April 7) |
| Predecessor | Jeito I: $630 million (closed 2021) |
| AUM (total) | €1.6 billion (tripled in five years) |
| Strategy | 15–20 clinical-stage European biopharmas in severe disease with high unmet need |
| Average investment size | Up to €150 million per company |
| Deployment to date | Investments in obesity (Alveus Therapeutics, $197M Series A), reproductive medicine, oncology, autoimmune/inflammatory, neurology, cardio-metabolic |
| Notable exits (Jeito I) | EyeBio (acquired by Merck, up to $3B), HI-Bio (acquired by Biogen, up to $1.8B), Neogene (acquired by AstraZeneca, $320M) |
Jeito II's final close is directly relevant to the pharmaceutical royalty and licensing ecosystem: Jeito-backed companies have been acquisition targets for major pharma (Merck, Biogen, AstraZeneca), and the fund's strategy of backing clinical-stage European companies through to advanced development creates a pipeline of potential licensing and royalty-generating transactions.
The increased per-company investment capacity (up to €150M vs. ~$100M for Jeito I) suggests Jeito II portfolio companies will reach later clinical stages before partnering or exiting, potentially commanding larger upfront payments and more structured royalty arrangements.
Disclaimer: The author is not a lawyer or financial adviser. Nothing in this article constitutes investment, legal, or financial advice. All information is provided for informational purposes only. Deal terms and figures are based on publicly available sources and may be subject to revision.
Member discussion